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Abstract: The major public health concern worldwide is coronary heart disease, with dyslipidemia as a major 
risk factor. Statin drugs are recommended by several guidelines for both primary and secondary prevention. 
Rosuvastatin has been widely accepted because of its efficacy, potency, and superior safety profile. Inflam-
mation is involved in all phases of atherosclerosis, with the process beginning in early youth and advancing 
relentlessly for decades throughout life. C-reactive protein (CRP) is a well-studied, nonspecific marker of 
inflammation which may reflect general health risk. Considerable evidence suggests CRP is an independent 
predictor of future cardiovascular events, but direct involvement in atherosclerosis remains controversial. 
Rosuvastatin is a synthetic, hydrophilic statin with unique stereochemistry. A large proportion of patients 
achieve evidence-based lipid targets while using the drug, and it slows progression and induces regression 
of atherosclerotic coronary lesions. Rosuvastatin lowers CRP levels significantly. The Justification for Use 
of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial was designed after 
the observation that when both low density lipoprotein and CRP were reduced, patients fared better than 
when only LDL was lowered. Advocates and critics alike acknowledge that the benefits of rosuvastatin in 
JUPITER were real. After a review, the US Food and Drug Administration extended the indications for 
rosuvastatin to include asymptomatic JUPITER-eligible individuals with one additional risk factor. The 
American Heart Association and Centers of Disease Control and Prevention had previously recognized the 
use of CRP in persons with “intermediate risk” as defined by global risk scores. The Canadian Cardiovascular 
Society guidelines went further and recommended use of statins in persons with low LDL and high CRP 
levels at intermediate risk. The JUPITER study focused attention on ostensibly healthy individuals with 
“normal” lipid profiles and high CRP values who benefited from statin therapy. The backdrop to JUPITER 
during this period was an increasing awareness of a rising cardiovascular risk burden and imperfect meth-
ods of risk evaluation, so that a significant number of individuals were being denied beneficial therapies. 
Other concerns have been a high level of residual risk in those who are treated, poor patient adherence, a 
need to follow guidelines more closely, a dual global epidemic of obesity and diabetes, and a progressively 
deteriorating level of physical activity in the population. Calls for new and more effective means of reduc-
ing risk for coronary heart disease are intensifying. In view of compelling evidence supporting earlier and 
aggressive therapy in people with high risk burdens, JUPITER simply offers another choice for stratification 
and earlier risk reduction in primary prevention patients. When indicated, and in individuals unwilling or 
unable to change their diet and lifestyles sufficiently, the benefits of statins greatly exceed the risks. Two 
side effects of interest are myotoxicity and an increase in the incidence of diabetes. 
Keywords: rosuvastatin, JUPITER study, statin drugs, C-reactive protein, dyslipidemia, cholesterol, primary 
prevention, cardiovascular risk, coronary heart disease, inflammation, low-density lipoprotein, high-density 
lipoprotein, diabetes, metabolic syndrome, Framingham risk score, Reynolds risk score, coronary artery 
calcification, carotid intima-media thickness, hypertension, obesity, HMG CoA reductase, mevalonate, 
prenylation, statin myopathy, pleiotropic, dolichol
Introduction
Cardiovascular disease (CVD) has been the leading cause of death for the past century in 
the United States (US), except for 1918, the year of an influenza pandemic. Even though Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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deaths from coronary heart disease (CHD) have fallen during 
the past 2 decades, the mortality rate from this disease remains 
the top cause of death in the US, and, by 2020, will attain that 
status globally as well. An analysis of the fall in CHD death 
rates from 1980 to 2000 using the IMPACT model of analyz-
ing data from the US National Center for Health Statistics1,2 
revealed that half of this decline was due to improvements in 
risk factors; 79% was attributable to primary prevention and 
21% to secondary prevention.3 Cholesterol reduction accounted 
for 42.7% of the death rate reduction in asymptomatic indi-
viduals, and for 34% in those with CHD. Use of statin drugs 
accounted for ,20% of the improvement in death rate during 
those 20 years. Reductions in systolic blood pressure accounted 
for 38.8% of the fall in asymptomatic individuals and 52.8% 
in patients with CHD. Decreased use of tobacco accounted for 
18.4% of the fall in deaths in asymptomatic individuals, and 
12.9% in those with CHD. While the contribution of statins, 
3-hydroxy-  3-methyl-glutaryl-coenzyme A reductase (HMGR) 
inhibitors, was surprisingly small, these results illustrate the 
power of primary prevention in the management of CHD. 
Given the lower usage of less potent statins in many of the 
years surveyed, the data simultaneously suggest that using statin 
drugs earlier in the disease, for longer periods of time during 
pathogenesis, and titrated to lower targets, has substantial 
unrealized potential.
The cardiovascular risk burden in the populations of nearly 
all countries continues to rise at an alarming rate, and recent 
analyses show that gains in reducing the death rate from CHD 
are now being offset by the pressure of increases in reversible 
factors of obesity,4 metabolic syndrome, and diabetes, along 
with the progressive aging of the population.5–8 Control of 
risk factors, while impressive thus far, have also fallen short 
of guideline targets and public health goals. Hence, there is 
ongoing interest in the best use of all elements of primary 
prevention in order to improve national heart health. Statin 
drugs are uniquely effective and prominently recommended 
in current guidelines. The potency and favorable benefit to 
risk ratio of rosuvastatin account for its increasing usage in 
primary and secondary prevention.
Significant and voluminous research concerning the bio-
chemistry, physiology, and clinical potential of measuring 
C-reactive protein (CRP), has intensified discussions concern-
ing the role CRP monitoring will have in current guidelines for 
primary prevention. The Justification for the Use of Statins in 
Primary Prevention: an Intervention Trial Evaluating Rosuvas-
tatin (JUPITER) trial, first reported in October 2008, presented 
evidence that a plasma CRP $ 2 mg/L reflects higher cardio-
vascular risk in asymptomatic individuals with low-density 
lipoprotein levels (LDL) ,130 mg/dL, and that they would 
benefit from rosuvastatin therapy.9 Following the JUPITER 
report, there was lively debate about the data, clinical signifi-
cance, and how the new information should be incorporated 
into clinical practice. Many fundamental questions concern-
ing primary prevention have since been revisited, including 
the early beginnings of CHD and its long incubation period; 
methods of evaluating risk in the population; how population-
based versus individual risk-based approaches may best be 
employed; role and refinement of global risk factor scores; 
choice and merits of nontraditional risk factors; assessment 
of multiple biomarker panels; role of imaging techniques in 
evaluation and ongoing therapy; value of advanced lipid test-
ing; weights assigned to traditional risk factors, cutoff values, 
and treatment targets, particularly LDL goals in guidelines; 
use of statins in primary prevention; reasons for low patient 
adherence with evidence-based therapies; causes of “clinical 
inertia” and lack of physician compliance with guidelines; and 
the etiologies, extent, and minimization of residual risk.
C-reactive protein
The fundamental role of inflammation in the pathogenesis of 
atherothrombotic disease is based upon strong evidence and 
is well-accepted.11–61 CRP protein is an acute phase reactant 
discovered by Tillett and Francis at Rockefeller University 
in 1930 in the blood of patients with pneumonia,62 was 
crystallized in 1947, and today, over 60 years later, there is 
still controversy about its physiology and applications in bio-
medicine. CRP protein is a pentraxin comprised of 5 subunits 
(Figure 1) which is primarily synthesized in the liver, and plays 
an active part in regulating the innate immune system. Since 
CRP mRNA levels rise in adipose tissue as CRP expression 
is enhanced in vitro by interleukin-6 (IL-6), adipose cells also 
have some ability to synthesize CRP. Innate immunity and 
adaptive immunity significantly modulate atherosclerosis,13,63,64 
with both pro- and anti-atherogenic potential.64–66
CRP binding offers a glimpse into teleological function. 
CRP binds to phosphocholine, commonly found in cell mem-
branes as well as in bacterial and fungal   polysaccharides. 
Phosphocholine is used by the placenta and nematodes to 
cloak them from their host immune system. Binding to 
complement C1q complex and factor H, CRP assists in 
human complement activity to promote antigen presenta-
tion and phagocytosis,67 essentially functioning as an innate 
opsonin. In addition, CRP binds directly with phagocyte Fcγ 
receptors,68 literally becoming the interface between innate 
immunity, C1q on complement, and inflammation, Fcγ on 
macrophages. Details of CRP binding to its ligands and their Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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implications have been recently reviewed.53 As an acute phase 
reactant during infections or diffuse tissue destruction, CRP 
concentrations may increase 50,000-fold quickly.69 A constant 
potent stimulus may sustain high circulating CRP concentra-
tions, depending upon synthetic capacity; the half-life of CRP 
in the circulation is about 19 hours.70 Hepatic synthesis is 
driven at the transcriptional level by IL-6, largely expressed 
by macrophages, T cells, and adipocytes.11,71   Several upstream 
cytokines also regulate hepatic CRP release. In part because 
there is overlap in signaling, plasma CRP values are related 
to other inflammatory markers. However, despite a plethora 
of research, the precise role(s) of CRP remain unclear.
Variation and significance of CRP levels
Baseline values of CRP are influenced by genetics.72,73 
Even after correction for age, CRP polymorphisms, and 
smoking, ancestry affects CRP levels, the highest values 
being found in blacks, with an average of 2.6 mg/L, fol-
lowed by   Hispanics, 2.51 mg/L, South Asians, 2.34 mg/L, 
whites, 2.03 mg/L, and East Asians with the lowest level 
at 1.01 mg/L.74 CRP levels also vary with the environment, 
eg, pollutant burdens;75 fiber intake,76–79 coffee ingestion,80 
and other dietary factors;26,29,81–84 smoking;85 body mass 
index;86,87 alcohol consumption;88,89 drugs, including con-
traceptives90 and hormone replacement therapy;91 chronic 
infections,92,93 and noninfectious inflammatory conditions, 
such as the autoimmune diseases,94–97 cancer,98 and poly-
cystic ovary syndrome;99–102 as well as multiple risk factors 
for atherosclerosis, including obesity, diabetes, metabolic 
syndrome, and hypertension. Triage of patients according 
to CRP levels generally control, correct for, and consider 
these variations.
Figure 1 A picture of C-reactive protein (CRP) from 1B09.pdb made using pymol.10 CRP is a pentameric molecule containing a recognition face that binds phosphocholine 
and calcium ions, and on the opposite side, an effector face that contains a C1q-binding site. Function depends upon Ca2+-dependent ligand binding. See text for details. 
Reproduced by permission of Skolstoe through wikipedia commons.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Since CRP binds to LDL and can be identified within 
atherosclerotic plaque,103,104 is involved with inflammatory 
atherogenic processes,105–116 is elevated in patients with 
acute (ACS) and chronic coronary syndromes117–120 with 
unfavorable plaque compositions in these syndromes,55 and 
is associated with complications of heart failure121 a causal 
role in atherothrombotic disease has long been suspected. At 
this time, causality remains unproven.107,122,123 One intriguing 
property of CRP is the associated inhibition of endothelial 
nitric oxide synthase in vitro124 and the relationship to 
impaired vasoreactivity and hypertension in such models.125 
Overall, the evidence for a role of CRP in endothelial cell 
dysfunction and monocyte activation in metabolic syndrome 
is impressive and difficult to ignore.126 The prevalence of this 
syndrome is approaching 53% in some populations (exclud-
ing those with diabetes)127 and the importance of endothelial 
dysfunction in pathogenesis is now unassailable.128
It is generally appreciated that a high CRP level (here-
after meaning hs-CRP [hs, highly sensitive] measurements) 
usually portends a poorer prognosis in patients with CHD, 
diabetes, hypertension, pre- or postoperative surgery, and 
vascular comorbidities. A high prevalence of elevated circu-
lating CRP levels in the general population has been known 
for some time. At the 53rd Annual Scientific Session of the 
American College of Cardiology, data were presented from 
the 1999–2000 National Health and Nutrition Examination 
Survey (NHANES) indicating that 47.1% of respondents 
aged 20 years or over had high CRP values.129,130 Levels 
were higher in females, the obese, and in the elderly, aged 
55 to 74. About one-third of the population has CRP levels 
above 3 mg/L.131 However, smaller elevations in CRP are 
even more common, and over half of the population has 
a CRP $ 2 mg/L.132 Such “minor” elevations in CRP also 
imply a poorer prognosis compared with lower values, both 
in the ill and the apparently healthy.133 Raised values of CRP 
strongly suggest clinical attention is necessary. Common 
associations of CRP elevations may reflect not only inflam-
mation but widespread tissue distress, degeneration, and/
or destruction, much of which may be age-related. At the 
other end of the continuum, a low CRP has been considered 
a measure of wellness,134 and as lifestyle becomes progres-
sively unhealthy in a population, CRP rises. As shown in 
the Monitoring Trends and Determinants in Cardiovascular 
Disease (MONICA) Augsburg Study, negative behaviors and 
factors, such as a poor quality “Western” diet with low intake 
of vegetables, fruits, and fiber, high consumption of saturated 
fats, poor physical fitness, and overfeeding and obesity, are all 
associated with higher CRP levels.135 In a global sense, when 
no overt disease is evident, the CRP level roughly follows the 
level of self-inflicted abuse. In these instances CRP elevations 
reflect poor lifestyle choices that lead to deranged metabolic 
signaling, inflammation, and the appearance and worsening 
of traditional risk factors during the early incubation period 
of atherosclerosis. As such, elevations tend to cluster with 
conventional risk factors, and teasing apart the significance 
has been difficult,136 but studies confirm that the properties of 
CRP and significance of changes are different. Lifestyle has 
a greater influence on CRP than does genetics.137 Conversely, 
sustained improvement in lifestyle, particularly weight loss 
with exercise, and measures that relieve the risk burden, 
including statins, all reduce plasma CRP levels.
In a review of hospital records of 22,962 patients in a 
large urban population, an analysis of change in CRP status – 
  normal (#3 mg/L) to elevated (.3 mg/L) and vice versa – and 
mortality, revealed a significant graded association between 
CRP levels and mortality.138 The patients were not healthy or 
chosen at random, but rather a cohort selected by physicians 
who believed their patients needed a CRP level performed. 
A change from normal to elevated CRP levels within a year 
was associated with a 6.7-fold hazard ratio (HR) for all-cause 
mortality during the following 4 years,   compared to subjects 
whose CRP remained normal. When CRP levels changed from 
elevated to normal, the HR halved to 3.5. In the hospital set-
ting as well, CRP levels reflect risk and subsequent survival, 
with a strong relationship to all-cause mortality, particularly 
in vascular diseases and cancer.139
In the elderly, high CRP values are associated with greater 
risk of all-cause mortality, especially in apolipoprotein E4 
carriers, as well as with cognitive decline.140 The Rancho 
Bernardo Study reported that the lower the circulating CRP 
level in elderly men, the greater their longevity, and plasma 
concentrations of IL-6 were inversely related to survival time 
in elderly women who did not use estrogen.141 Finally, the 
classic paper that showed CRP was a stronger predictor of 
cardiovascular events than LDL, and measuring both together 
provided better prognostic information than screening for 
either alone, firmly established the potential clinical signifi-
cance of following circulating CRP concentrations.142 This 
study also demonstrated the inverse relationship between 
CRP levels and the probability of event-free survival.
The work cited above supports the significance of circu-
lating CRP levels in “ordinary” individuals as a sensitive but 
nonspecific index of quality of lifestyle prior to the diagnosis 
of disease, as a screen for risk refinement beyond traditional 
risk factors, and as an index that reflects the intensity of either 
the amount of inflammation or volume of cell distress.133Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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When CRP was compared to other inflammatory 
markers as a predictor of relative risk of hard coronary 
events (postmenopausal women, highest versus lowest 
quartile) relative risk scores were CRP, 4.4, serum amyloid 
A, 3.0, soluble intercellular adhesion molecule type 1, 2.6, 
IL-6, 2.2, total cholesterol, 2.4, LDL, 2.4, apolipoprotein 
B-100, 3.4, high-density lipoprotein (HDL), 0.3, and for the 
ratio total cholesterol/HDL, 3.4.35 The predictive power of 
CRP remained significant for LDL values ,130 mg/dL. Of all 
nontraditional risk factors, CRP is the most studied, with 
over 34,000   general PubMed results, and 12,500 in con-
nection with CVD, authored by investigators around the 
world over an extended period of time. CRP is involved in 
basic pathophysiology, and/or reflects additional risk and/or 
has predictive power in a number of CVDs, equivalents, or 
comorbidities, which include hypertension,143–151 hyperten-
sion and blood pressure variability,152 percutaneous coronary 
intervention,153,154 re-endothelialization,110 stent implantation,155 
coronary artery bypass surgery,156–158 heart failure,159–167 
peripheral arterial disease,168,169 carotid artery disease,170 
sudden cardiac death (SCD),171–173 atrial fibrillation,174–176 
ventricular tachycardia after myocardial infarction (MI) and 
implantable cardioverter-  defibrillator implantation,177 calcific 
aortic valve disease,178 venous thromboembolism,179,180 pul-
monary arterial hypertension,181 diabetes,116,182–186 metabolic 
syndrome,87,93,168,180,185,187–199   rheumatic mitral stenosis,200 chronic 
lung disease and asthma,201–203 chronic kidney disease,154,204–206 
obstructive sleep apnea,207–208 air pollution vis-à-vis inflamma-
tion and cardiac risk,75,209,210 obesity,137,197,211–223 eclampsia,224 
blood concentrations of reactive oxygen species,225 depression 
in the obese,211 depression associated with coronary artery 
disease,226 and HIV disease progression.225 Statins have been 
found useful in many of these clinical situations. The prepon-
derance of the evidence, from many diverse sources, indicates 
that CRP measurement has significant broad-based value and 
is also uniquely related to vascular disease.
CRP and genetic studies
CRP genetic (pentraxin-related) polymorphisms exist, which, 
together with diet and other lifestyle factors, contribute to 
significant interindividual variation in plasma CRP levels, 
as well as differences in responses to therapeutic agents.227 
Such variants in the CRP locus may account for 30% to 50% 
of the phenotypic variation in CRP levels,228 and may also 
explain some ethnic differences.229 CRP concentrations are 
16% lower, for instance, in Asians, but 26% higher in black 
people than in whites.230 In addition, other genetic loci that 
encode for upstream cytokines (IL-6, IL-1, tumor necrosis 
factor α) that affect CRP synthesis influence CRP levels, as 
well as genes related to obesity and insulin resistance.187
Mendelian randomization, the random assortment of 
genes that occurs during reproduction, provides a method for 
assessing cause and effect that is not influenced by reverse 
causation.231–233 By comparing natural variation in known 
genes and phenotype, strengths of environmental influ-
ences may be inferred.234 A large genome-wide association 
(n = 17,967) and replication study (n = 13,615) examined the 
association of genetic loci with plasma CRP concentrations 
and risk of CHD.235 The authors found that genetic variants 
expected to lower the CRP expression by about 20% did not 
reduce CHD risk by the predicted amount of 6%. The dis-
cordance between anticipated versus actual CRP phenotype 
argued that, in genetic variants, high CRP levels throughout 
life do not cause increased risk for ischemic heart disease. 
Several limitations to the study, and in the use of Mende-
lian randomization generally, were identified.236 Another 
Mendelian randomization study of 47,000 individuals from 
the general population revealed a comparable situation else-
where: high plasma CRP values were robustly associated 
with higher risk of atrial fibrillation, but not with genetically 
elevated CRP levels.176
Causation versus predictive utility
The Emerging Risk Factors Collaboration (ERFC) reported 
a meta-analysis of records of 160,309 people with medical 
histories of vascular disease, associating logeCRP concen-
trations with conventional risk factors and inflammatory 
markers.237 Their data confirmed that downstream markers of 
inflammation, especially fibrinogen levels, but also the leu-
kocyte count, plasma albumin concentration, and erythrocyte 
sedimentation rate, were associated with CRP levels. As the 
investigators adjusted for conventional risk factors, the asso-
ciations of CRP levels with risk of CHD weakened, but the 
most significant adjustment was for fibrinogen perturbations 
during inflammation. Hepatic synthesis of this protein is also 
regulated by IL-6. Hence, the ERFC concluded that most of 
the association of CRP with coronary artery disease depends 
upon conventional risk factors and fibrinogen levels.18,238–240 
Their views are consistent with findings using Mendelian 
randomization discussed above, noting a disparity between 
CRP-related phenotypes, coronary risk, and subsequent 
coronary events.
Interestingly, after adjusting for conventional risk fac-
tors, the relative risks for CHD in this meta-analysis were 
CRP, 1.37, non-HDL cholesterol, 1.28, and systolic blood 
pressure, 1.35. Therefore, despite the conclusion, their data Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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actually confirmed that CRP concentrations have a significant 
predictive association with risk of CHD, stroke, and vascular 
and nonvascular mortality.
While the ERFC appears to argue against a causative 
role of CRP in atherosclerosis, the issue is far from settled, 
since there is much convincing basic science that requires 
specific refutation.126 In addition, a significant putative 
role for the monomeric form of CRP (mCRP) has been 
proposed.241 Mediated by activated platelets, formation of 
mCRP,242 a conformationally distinct isoform which is pro-
thrombotic243 and inflammatory,244 might confound conclu-
sions if monomeric conversion of CRP from the pentameric 
moiety (pCRP) – commonly measured as hs-CRP – were 
not considered. Indeed, it has been shown that mCRP local-
izes monocyte-mediated inflammation in the atherosclerotic 
plaque, and may be deposited in plaques but not in healthy 
vessels, whereas pCRP is not found in either healthy or dis-
eased arteries.244 Moreover, mCRP and pCRP have differing 
actions on neutrophil migration and thrombus evolution. The 
various metabolic roles of pCRP and mCRP are expertly 
reviewed in an editorial accompanying the aforementioned 
paper.115 There is further evidence that mCRP inserts into 
lipid raft microdomains within endothelial cell membranes, 
rather than binds to surface proteins, as a complex function of 
membrane cholesterol content. The result of this incorpora-
tion is endothelial cell activation, as part of an early inflam-
matory step in the atherosclerotic process.245 These data are 
but a small part of the burgeoning scientific literature that 
underscores the importance of CRP in atherothrombosis, and 
the need for further research.
A randomized trial using a drug that targets CRP will be 
necessary to decide whether or not CRP is causally involved 
in atherogenesis. However, even if proof of CRP participa-
tion in the atherothrombotic process is incomplete, separate 
evidence indicates that measurement of CRP levels is useful 
in predicting and monitoring particular groups of patients. 
For instance, AFCAPS-TexCAPS found that patients with 
higher CRP may anticipate a better response to statins,246 
and selection of patients with high CRP levels in different 
circumstances adds to absolute risk assessment.142,247,248 As 
mentioned above, the ERFC, a large meta-analysis, reported 
a consistent 1.6-fold rise in vascular risk for each 1-SD rise 
in CRP levels.237
After de Beer reported that elevations in CRP levels 
predicted a poor outcome after MI,249 baseline levels were 
found to predict future cardiac events in stable and unstable 
angina.250,251 These observations were extended to people 
without heart disease in whom baseline CRP measurements 
also correlated with future cardiac prognosis.135,252 Lowering 
CRP concentrations in patients without elevations in LDL 
following statin administration improved prognosis.248,253 
Reporting bias, with multiple ways of comparing CRP values, 
together with publication bias in CRP studies, may hamper 
full evaluation of prognostic capability.254 Several studies 
confirm that patients with higher CRP levels are at greater 
risk than those with lower values.118,255 These data support 
the view that measurement of CRP improves prediction of 
risk.118,256 Another approach, as suggested by the American 
Heart Association, the CDC, and the Canadian Cardiovas-
cular Society, is that patients with heart disease falling in the 
“intermediate risk” category – with a Framingham Risk Score 
(FRS) of 10% to 20% – have increased CHD risk if CRP 
levels are elevated, and may be considered for statin therapy. 
The Canadian Cardiovascular Society recommends prophy-
lactic statins for men .50 years and women .60 years with 
a CRP level .2 mg/L, and who are otherwise considered 
“intermediate risk”.257 Prior to the JUPITER study,9 consid-
erable data showed that CRP levels $2 mg/L significantly 
raised risk, but currently laboratory reports continue to men-
tion that CRP levels 2 to 3 mg/L reflect an average risk, and 
levels .3 mg/L reflect greater than average risk.258 Large 
prospective cohort studies reported age-adjusted relative 
risks for coronary artery disease from about 2.0 to 3.0 for the 
highest versus the lowest levels of CRP, again documenting 
a consistent association with heart disease that has predictive 
power.12,86,259
Some studies report that CRP does not discriminate 
sufficiently,260,261 adds little to traditional risk factors,86 in 
particular the FRS, and hence may lack cost-effectiveness. 
On the other hand, investigators have reported remarkable 
discrimination in a number of clinical settings,255 have 
found that when CRP is added to existing risk evaluation 
systems predictive power is enhanced,256,262–268 and reported 
that cost-effectiveness is indeed significant.269–271 All things 
considered, CRP is admittedly imperfect, as are all risk fac-
tors. However, it is much better than other nontraditional 
risk factors when used to refine risk, particularly when used 
along with traditional risk factors. In conclusion, CRP is an 
acknowledged sensitive marker of systemic inflammation,11 
and in primary prevention, over 40 reports from prospective 
studes and 2 meta-analyses report a consistent association 
of CRP with subsequent CHD events.86,272,273 One evolving 
view is that traditional risk factors and scores should be 
used initially, and CRP measured in patients at intermediate 
risk or in complex patients. If elevated, a more aggressive 
therapeutic stance may be warranted.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Although lifestyle measures and some pharmacological 
agents do reduce CRP levels, statins are most frequently 
employed, and lower CRP levels about 15% to 35%.274,275 
Rosuvastatin and atorvastatin in higher doses have the most 
significant CRP-lowering properties.274
Rosuvastatin
The word cholesterol derives from the Greek chole- (bile), 
stereos (solid), and –ol, the chemical suffix for alcohol. First 
identified in gallstones in 1769, the modern name was begun 
by chemist Eugène Chevreul in 1815. By 1971 Japanese 
biochemist Akira Endo began seeking compounds to lower 
cholesterol, and in 1987 Merck began marketing lovastatin 
isolated from Aspergillus terreus.
The endogenous biosynthesis of cholesterol occurs 
through the mevalonate pathway (Figure 1). HMGR is a 
highly regulated enzyme which catalyzes the rate-limiting 
step in cholesterol synthesis. Although HMGR is located 
within membranes of the endoplasmic reticulum, its 
catalytic domain remains active after it is cleaved from the 
transmembrane portion of the enzyme. The reduction of 
HMG to mevalonic acid involves the transfer of 4 electrons, 
using 2 molecules of nicotinamide adenine dinucleotide 
(NADPH) as a reductant in 2 steps. The carboxyl moiety of 
hydroxymethlyglutarate esterified to the thiol of CoA is first 
reduced to an aldehyde, and then to an alcohol. Statin drugs 
are highly efficient competitive inhibitors of HMGR.
Clinical pharmacology
Rosuvastatin (Figure 3) is a sulfur-containing, hydrophilic 
statin with multiple sites that form a strong interaction 
with HMGR and therefore provide more potent enzyme 
inhibition than other statins. Stereochemical details of 
the molecular binding between rosuvastatin and HMGR 
have been detailed elsewhere.276,277 Rosuvastatin, like 
other statins, is a competitive antagonist of HMGR, 
competing directly with the endogenous substrate for the 
active site cavity of the enzyme. Rosuvastatin employs 
a modified hydroxyglutaric acid moiety that mimics 
the 3-hydroxyglutaryl unit of the substrate, HMG CoA, 
and the mevaldyl CoA transition state intermediate. 
The pyrimidine ring in rosuvastatin binds tightly to the 
HMGR enzyme in the same area that normally binds the 
CoA component of the endogenous substrate HMG CoA. 
As a synthetic, “type 2”, or second-generation statin, 
rosuvastatin contains a fluorophenyl group which pro-
vides additional polar interactions that strengthen bind-
ing to HMGR. All told, rosuvastatin has an affinity for 
Acetyl CoA
Acetoacetyl CoA
HMG-CoA
Mevalonate
Isopentenyl-pyrophosphate
Geranyl pyrophosphate
Squalene
2,3-Oxydosqualene
Lanosterol
Desmosterol
Cholesterol
Additional terpenoid hormones, including steroid hormones, bile acids, vitamin D
Decaprenyl pyrophosphate
Ubiquinone (CoQ10)
HMG CoA reductase is blocked by statins here
Farnesyl pyrophosphate Geranylgeranyl pyrophosphate
Polyprenyl pyrophosphate
Dolichol
HMG CoA reductase is blocked by statins here
Figure 2 Cholesterol is synthesized via the mevalonate pathway. Acetyl-CoA forms 3-hydroxyl-3-methylglutaryl CoA (HMG-CoA) in several steps. The conversion of 
3-hydroxy-3-methylglutaryl (HMG)-CoA to mevalonate, the rate-limiting step in cholesterol synthesis, is catalyzed by HMG-CoA reductase (HMGR), an enzyme within the 
endoplasmic reticulum. Rosuvastatin is an efficient competitive inhibitor of HMGR, reducing not only mevalonate levels, but also prenylated downstream products. The 
post-translational process of prenylation is needed for the function of small G proteins, including geranylgeranylation of Rho, Ras, and Rab, necessary for cellular signaling, 
transduction, and intermembrane translocation. As beneficial as statins are, there are obligatory molecular consequences inherent in their use, some related to their beneficial 
pleiotropic actions, but also to their side effects. Many steps and enzymes are omitted for clarity.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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the HMGR active site that is .104-fold higher than that 
of HMG CoA.
Rosuvastatin is administered in its active acid form, 
meaning that the pharmacophore binding to the HMGR needs 
no transformation for activity compared with simvastatin or 
lovastatin, which are administered as lactones, a portion of 
which is hydrolyzed to the active acid form. Rosuvastatin is 
a hydrophilic statin, with relatively greater hepatoselectiv-
ity due to a unidirectional carrier-mediated active transport 
system. Hydrophilic statins tend to be retained in the liver, 
in part because they cannot passively diffuse out, whereas 
lipophilic statins concentrate in nonhepatic tissues. This 
property of hydrophilic statins is believed to account for 
fewer adverse events.278,279 As a result, rosuvastatin joins 
fluvastatin and pravastatin among statins least likely to 
produce myotoxicity.
Peak plasma concentration (Cmax) is reached 3 to 5 hours 
after oral administration,280 and both Cmax and the area under 
the plasma concentration-time curve (AUC) increase almost 
linearly with the dose. Absolute bioavailability is about 
20%. Rosuvastatin is 88% bound to plasma proteins, chiefly 
albumin. Mean volume of distribution under steady-state 
conditions is ≈134 L. The half-life of rosuvastatin is 19 hours, 
the longest of the available statins. While pharmacokinetics 
do not differ meaningfully among white, Hispanic, or black 
individuals, Asians have about double the median exposure 
(Cmax and AUC) than whites. As a result, lower starting doses 
are advised in Asian-Americans.
Elimination is primarily in the liver, with ≈10% through 
the action of cytochrome CYP2C9, producing a metabolite, 
N-desmethyl rosuvastatin, having up to half the potency of 
rosuvastatin. After oral administration, 90% of rosuvastatin 
and its metabolites are excreted in the feces. Following an 
intravenous dose, about 72% of total body clearance is via 
the hepatic route, and 28% through the kidneys. Lipophilic 
statins must be metabolized to water-soluble forms for renal 
excretion, reactions that depend upon CYP450 isoenzymes. 
Compared to atorvastatin and some other statins, rosuvastatin 
has an advantage, since it is not metabolized predominantly 
through CYP3A4, eliminating many potential drug and food 
interactions. There are, however, other variables affect-
ing pharmacokinetics and potential dose-related toxicity. 
P-glycoprotein (P-gp, also called ABCB1), an intestinal 
ATP-dependent drug efflux pump located in epithelial plasma 
membranes, prevents cellular uptake of xenobiotic foreign 
substances. P-gp also transports a number of endogenous 
biochemicals and drugs across cell membranes, noteably 
digoxin, and is inhibited by several statins. Available data 
do not indicate that rosuvastatin inhibits P-gp significantly, 
and therefore interactions with P-gp substrates and inhibi-
tors, many of which are also CYP3A4 interactants, are not 
clinically relevant. Another potential interaction involves a 
hepatic uptake transporter, organic anion transporting poly-
peptide 1B1 (OATP1B1).281 Cyclosporine and gemfibrozil 
are OATP1B1 inhibitors, which may explain coadministra-
tion interactions.282 (See further discussion below under 
Side effects).
For each 39 mg/dL (1 mmol/L) fall in LDL, there is a 21% 
reduction in major cardiovascular events.283 Atorvastatin low-
ers LDL up to 60% at a maximal dose of 80 mg. Rosuvastatin 
lowers LDL by 45% to 63% (5 mg, 38%; 10 mg, 43%; 
20 mg, 48%; 40 mg, 53%; 80 mg, 58%), reduces triglyceride 
levels by 10% to 35%, and raises HDL by 8% to 14%.179,284 
The rise in HDL is believed to be due to a combination of 
a lower apolipoprotein A-1 (apoA-1) catabolism, raised 
hepatic apoA-1 synthesis, peroxisome proliferator-activated 
receptor-α activation and inhibition of cholesteryl ester 
transfer protein.280 Of all the statins, rosuvastatin has the 
lowest half maximum inhibitory concentration for cholesterol 
synthesis in the liver. The milligram-equivalent reductions 
in LDL and elevations in HDL are superior to those of other 
statins,179 thereby achieving evidence-based LDL targets 
in a higher portion of patients and greater success during 
intensive LDL reduction (Table 1). Rosuvastatin also lowers 
small, dense LDL concentrations. Although the reductions 
in LDL are dose-related, increasing the dose beyond 10 mg 
generally produces progressively smaller absolute reductions 
in LDL levels per unit.
Clinical studies with rosuvastatin
The Galaxy Program285 is a long-term, multi-trial research 
initiative sponsored by AstraZeneca, a planned portfolio 
of studies to investigate and support use of rosuvastatin to 
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Figure 3 The structure of rosuvastatin, uniquely containing sulfur, a fluorophenyl 
group, and a modified hydroxyglutaric acid moiety. The IUPAC name of rosuvastatin is   
(E,3R,5R)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan- 
2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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improve cardiovascular events and outcomes. The JUPITER 
study is one component, among others such as ASTEROID, 
METEOR, and CORONA. JUPITER sought to determine 
whether 20 mg of rosuvastatin could lower the number of 
major cardiovascular events in patients with acceptable LDL 
(under current guidelines) and elevated CRP levels, using a 
combined end point of death, MI, stroke, unstable angina or 
revascularization, and is further described below.
The Measuring Effects on Intima-Media Thickness: 
an Evaluation of Rosuvastatin (METEOR) trial random-
ized 984 asymptomatic participants with a mean age of 
57 years, FRS , 10%, modest carotid intima-media thickness 
(CIMT) thickening (1.2 to ,3.5), and elevated LDL (mean, 
154 mg/dL) to either rosuvastatin 40 mg or placebo.286,287 
The primary end point was the annualized rate of change in 
maximum CIMT at 12 sites during the 2-year study period. 
The rate of progression of maximum CIMT was significantly 
reduced by rosuvastatin therapy, but actual lesion regression 
was not achieved.
The Controlled Rosuvastatin Multinational Trial in Heart 
Failure (CORONA) was conducted from 2003 to 2005 in 
371 sites in 21 countries.288 The study randomized 5011 
patients $60 years of age with chronic New York Heart 
Association (NYHA) class II, III, or IV ischemic systolic 
heart failure and an ejection fraction less than 40% to either 
rosuvastatin 10 mg or placebo. Median follow up was 
32.8 months. There was a sharp fall in mean LDL (137 mg/dL) 
and CRP (3.1 mg/dL) at baseline to 3-month values of 76 and 
2.1 respectively. The primary end point of the study was a 
composite of cardiovascular-related death, nonfatal MI, and 
nonfatal stroke. Secondary outcomes were total and cardio-
vascular mortality, time to first coronary event, and number 
of hospitalizations. By the end of the follow-up period, almost 
one-third of the participants sustained one end point event. 
There was no significant effect of rosuvastatin on primary or 
secondary end points, but a subsequent analysis suggested 
that those with CRP $ 2.0 had a 13% relative risk reduction 
and better outcomes.289 The Gruppo Italiano per lo Studio 
della Sopravvivenza nell’Infarto Miocardico Heart Failure 
(GISSI-HF) trial, which took place at 357 medical facilities 
in Italy, also prospectively randomized 4574 patients with 
NYHA class II-IV heart failure to rosuvastatin 10 mg or pla-
cebo, without an improvement in the primary end point.290 In 
GISSI-HF the event rate was similarly high, with over half the 
patients sustaining a cardiovascular death or hospitalization, 
reporting a 29% all-cause mortality during a follow-up of 
over 4 years. Although no explanation was forthcoming, it is 
apparent that these patients were quite ill with well advanced 
structural changes and pathophysiology. A recent commentary 
hypothesized that progression beyond a critical threshold in 
the pathogenesis of heart failure may have precluded any 
beneficial effect, citing the need for additional trials.291
Likewise, in A Study to Evaluate the Use of Rosuvas-
tatin in Subjects on Regular Hemodialysis: An Assessment 
of Survival and Cardiovascular Events (AURORA), 2776 
patients with end-stage chronic renal disease (ESRD) at 
284 dialysis facilities in 25 countries were randomized to 
rosuvastatin 10 mg or placebo, and there was no significant 
difference between groups in a primary end point of time to a 
major cardiovascular event, even though LDL and CRP levels 
were substantially reduced in the treatment group.292 In this 
population the event rate of MI, stroke and cardiovascular 
death was .35%, again reflecting complex, advanced dis-
ease and extremely high absolute risk. One author proposed 
that in both ESRD and calcific aortic stenosis, once disease 
has progressed sufficiently, particularly with anatomical 
changes, statins may become unable to help achieve the 
end points chosen.293 When begun earlier during aortic 
sclerosis or mild stenosis, improvement is more likely than 
when stenosis is advanced. In ESRD, since cardiovascular 
mortality rises sharply by the time a patient requires dialy-
sis, the threshold for benefit may have been passed prior to 
enrolling in the study.
The results of the A Study to Evaluate the Effect of 
Rosuvastatin on Intravascular Ultrasound-Derived Coronary 
Atheroma Burden (ASTEROID) study offer insight into the 
effects of rosuvastatin on the atherosclerotic process using 
two different, complementary techniques. First, monotherapy 
with 40 mg rosuvastatin for 24 months, which lowered 
LDL and raised HDL by about 53% and 15% respectively, 
Table 1 Rough equivalent doses of rosuvastatin
% Reduction in LDL  Rosuvastatin Atorvastatin Simvastatin Fluvastatin Lovastatin Pravastatin
30–40 5 mg 10 mg 20 mg 80 mg 40 mg 40 mg
40–45 5–10 mg 20 mg 40 mg N/A 80 mg 80 mg
46–50 10–20 mg 40 mg 80 mg N/A N/A N/A
50–55 20 mg 80 mg N/A N/A N/A N/A
56–60 40 mg N/A N/A N/A N/A N/A
Abbreviation: LDL, low-density lipoprotein.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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significantly reduced atheroma volume in major coronary 
arteries that were angiographically normal or were stenosed, 
as assessed with intravascular ultrasound.294 Second, using 
quantitative coronary angiography (QCA), rosuvastatin 
decreased percentage diameter of coronary stenoses and 
improved minimum lumen diameter.295 Intravascular ultra-
sound images the coronary artery wall in proximal areas with 
minimal lumen stenosis, and QCA examines luminal narrow-
ing in different segments of the coronary tree. Concordance 
of the findings strongly suggests rosuvastatin causes both 
slowing of progression of atherosclerosis and lesion regres-
sion in concert with LDL levels #70 mg/L (1.81 mmol/L). 
Reduction of luminal diameter, as detected by QCA, cor-
relates with lower risk of future coronary events296 and 
subsequent mortality.297 Interestingly, changes in atheroma 
volume, when stratified above or below a median change of 
−37.1% in LDL and −21.4% in CRP levels, was greatest in 
those with reductions in both LDL and CRP (−2 mm3), less 
when CRP fell but not LDL (−1 mm3), progressed when LDL 
fell but CRP was high (+2 mm3), and progressed the most 
when both LDL and CRP were high (+8 mm3).294
The JUPITER study
Based upon (a) the ability of CRP to predict future vascular 
events,142,299–301 and (b) of statins to lower CRP,301 together 
with (c) additional evidence that the benefits of statins were 
greater when both LDL and CRP levels were lowered,249,253 
and (d) a post-hoc analysis of the AFCAPS/TExCAPS 
study that indicated that healthy individuals with elevated 
CRP levels and normal LDL values could benefit from sta-
tin therapy,246 the global, multicenter JUPITER study was 
designed.9,302,303 After screening some 90,000 prospects, 
JUPITER enrolled 17,802 men ($50 years) and women 
($60 years). The study population was not diagnosed with 
either CHD or diabetes, and had “normal” LDL levels 
(LDL , 130 mg/dL), but high hs-CRP levels ($2.0 mg/L, 
median, 4.2 mg/L).
Participants were randomized to either treatment with 
rosuvastatin 20 mg daily or placebo. Participants’ median 
age was 66 years, and they comprised 62% men, 38% 
women, 71% Caucasians, 12.5% blacks, and 12.7% His-
panics (Table 2). Although free from clinical illness, the 
JUPITER population was not healthy, with 41% qualifying 
for the metabolic syndrome cluster of risk factors, 16% 
using tobacco, and 11.5% with a family history of premature 
heart disease. The cohort was fairly representative of the 
general population, with as-yet undetected, but substantial 
risk   burden. This is an important point, since sometimes the 
term “healthy” may automatically be interpreted to mean “no 
treatment is necessary”.
The primary end point composite included a nonfatal 
MI, nonfatal stroke, hospitalization for unstable angina, an 
arterial revascularization procedure, or confirmed death from 
a cardiovascular cause. The secondary end points included 
the individual components of the primary end point and all-
cause mortality.
Although planned as a 5-year study, when patients in 
the rosuvastatin group had significantly fewer events and 
deaths than the controls, an independent data and safety 
monitoring board performed an interim efficacy analysis, 
and the trial was stopped after a median follow-up time of 
1.9 years. About 75% of the treated participants were still 
taking rosuvastatin when the trial was ended. At that time 
there were 142 first major cardiovascular events in the rosu-
Table 2 Baseline clinical data in the JUPITER trial
Characteristic Treated group  Placebo group
Age, years (%) 66 (median)  66
Female sex, number (%) 3426 (38.5)  3375 (37.9)
ethnicity
  White, number (%)
  Black, number (%)
  Hispanic, number (%)
6358 (71.4)
1100 (12.4)
1121 (12.6)
6325 (71.1)
1124 (12.6)
1140 (12.8)
Body mass index, kg/m2 28.3 (median) 28.4
Family history, number (%) 997 (11.2) 1048 (11.8)
Tobacco use number (%) 1400 (15.7) 1420 (16.0)
Systolic blood  
pressure, mm Hg
134 (median) 134
Diastolic blood  
pressure, mm Hg
80  80 
CRP
  mg/L
  nmol/L
4.2 (2.8–7.1)a
40.0 (median)
4.3 (2.8–7.2)
40.9
Triglycerides
  mg/dL
  mmol/L
118 (median)
1.33
118
1.33
Total cholesterol
  mg/dL
  mmol/L
186
4.82
185
4.79
LDL cholesterol
  mg/dL
  mmol/L
108
2.8 
108
2.8
HDL cholesterol
  mg/dL
  mol/L
49
1.27
49
1.27
Glucose
  mg/dL
  mol/L
94
5.22
94
5.22
HbA1c % 5.7 (5.4–5.9) 5.7 (5.5–5.9)
Metabolic syndrome (%)b 3652 (41.0) 3723 (41.8)
Notes: aInterquartile range;  bMetabolic syndrome was defined according to the 
National Heart, Lung, and Blood Institute definition or American Heart Association 
consensus criteria.
Abbreviations: HbA1c, glycated hemoglobin; LDL, low-density lipoprotein.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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vastatin group, and 251 events in the placebo group, for a 
44% reduction in first major cardiovascular events (HR 0.56, 
95% confidence interval [CI] 0.46 to 0.69; P , 0.00001). 
There was also a 54% drop in nonfatal MI, a 48% reduction 
in nonfatal stroke, and a 47% fall in the cumulative inci-
dence of hard end points of MI, stroke, or cardiovascular 
death in the rosuvastatin group (Table 3). In addition, there 
was a significant reduction in all-cause mortality of 20% in 
the treatment group, comparatively greater than in previous 
statin trials considering the duration. Rosuvastatin lowered 
CRP levels by 37%, with a 12 month mean of 2.2 mg/L, and 
lowered LDL by 50%, with a mean treated value of 55 mg/dL. 
Without a control group with normal CRP levels, whether 
CRP reduction was responsible for the observed benefits 
could not be answered.
The number needed to treat to prevent a first major 
primary end point event in 2 years was 95, falling to 31 in 
4 years, and 25 for 5 years of treatment with rosuvastatin. 
The cardiovascular event rate in the rosuvastatin group was 
about 1 in 100, compared to approximately 2 in 100 in the 
placebo group, an absolute risk reduction of ≈1.2% for the 
1.9-month study. Hence 25 individuals would require treat-
ment for 5 years to prevent a single event, an absolute risk 
reduction of about 4%. Note that in primary prevention the 
baseline risk and event rate is low, so there is relatively less 
benefit in absolute risk anticipated. It is also instructive to 
compare the improvement in absolute risk achieved using the 
Mediterranean diet as the intervention, which may exceed 
5% in some situations.304,305
JUPITER recorded 270 new cases of diabetes in the 
treatment group compared to 216 in the control group, and 
a rise in median glycated hemoglobin (HbA1c) levels, also 
noted in prior statin studies, amounting to a 25% increase 
in physician-reported incidence of diabetes over a 1.9-year 
period. There were 10 cases of myopathy in the rosuvastatin 
group versus 9 in the control group, with only 1 instance of 
rhabdomyolysis associated with rosuvastatin, numbers that 
are consistent with previous rosuvastatin trials.
Given prior data that CRP values improved prediction 
of risk, JUPITER suggested that a seemingly healthy patient 
population at high risk, previously ineligible for statin 
therapy, may benefit from rosuvastatin treatment, guided by 
the CRP level.306 Attention was focused on the large body of 
research that points to inflammation as a common denomina-
tor in atherothrombosis, ie, that inflammation matters at a 
clinical level.57 JUPITER, called a landmark study immedi-
ately after presentation, has since been the subject of many 
editorials, discussions, and intense debate. An online poll 
conducted by the New England Journal of Medicine followed 
publication, with 2553 votes cast over 18 days.307 Half of the 
respondents believed JUPITER data should change screening 
in the general population, with the remainder voting against 
any change. Similarly, the votes for and against a change in 
the therapeutic use of statins based upon JUPITER results 
were about evenly divided.
Subsequent analyses pertaining  
to JUPITER
Using data from 1999–2004 NHANES and applying NCEP 
ATP III 2004 Update (ATP III) criteria, Spatz et al308 
  calculated that 57.9% of older adults (men $ 60 years, 
women $ 50 years) are either taking a statin (24.4%) or eligi-
ble for a statin (33.5%). If one includes individuals satisfying 
strict JUPITER criteria – no history of cardiovascular disease, 
LDL , 130 mg/dL, and CRP $ 2 mg/L – an additional 13.9% 
of the age group mentioned above, or nearly 8 million people, 
Table 3 JUPiTeR trial: comparison of outcomes between treated and nontreated patients
End point Patients in subgroup 
rosuvastatin (n = 8901)
Patients in subgroup  
placebo (n = 8901)
Hazard ratio (95% CI)
Primary end pointa  142 251 0.56 (0.46–0.69)
Any Mi 31 68 0.46 (0.30–0.70)
Nonfatal Mi 22 62 0.35 (0.22–0.58)
Any stroke 33 64 0.52 (0.34–0.79)
Nonfatal stroke  30 58 0.52 (0.33–0.80)
Revascularization 71 131 0.54 (0.41–0.72)
Hospitalization for unstable angina 16 27 0.59 (0.32–1.10)
Revascularization or hospitalization  
for unstable angina
76 143 0.53 (0.40–0.70)
Mi, stroke, or death from  
cardiovascular causes
83 157 0.53 (0.40–0.69)
Any death 198 247 0.80 (0.67–0.97)
Notes: aPrimary end point: composite of nonfatal MI, nonfatal stroke, hospitalization for unstable angina, revascularization, and death from cardiovascular causes.
Abbreviations: CI, confidence interval; MI, myocardial infarction.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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would become eligible for rosuvastatin therapy. If expanded 
JUPITER criteria were used – LDL between 130 and 
160 mg/dL and CRP $ 2 mg/L – another 5.3%, or 3   million 
individuals, would become statin-eligible. Hence a grand 
total of just under 80% of the older population would have 
an indication for statin therapy. Compared to the remaining 
20%, the “JUPITER group” was composed of more females, 
was older with a higher body mass index, and tended to have 
hypertension and metabolic syndrome. They also shared many 
characteristics with ATP III subjects, particularly the use of 
tobacco, visceral obesity, and hypertension.   Interestingly, 
the investigators308 noted that in the Women’s Health Study, 
about 20% of the women with low and intermediate FRS 
were reclassified by using the Reynolds risk score, which 
incorporates CRP values.35,256,263 These findings support the 
growing realization that risk is greater than generally believed, 
and the validity of CRP-guided risk reduction.
Michos and Blumenthal309 also estimated the prevalence 
of JUPITER-eligible individuals in the US population using 
NHANES 1999–2004 data. They found about 6.5 million 
individuals would be added if strict JUPITER criteria were 
followed. Based upon the number needed to treat (NNT) of 
25 at 5 years, they estimated about 260,000 cardiovascular 
events could be prevented with rosuvastatin therapy. A sub-
sequent recalculation, after adding the number of venous 
thromboses that would be avoided, raised the number to about 
500,000 per annum.
Ridker310 clarified aspects of the JUPITER study in mid-
2009, observing that all prespecified subgroups benefited by 
rosuvastatin therapy, including those participants considered 
at low risk. The decision to terminate the study early was 
based on rigorous pre-agreed principles. It was noted that the 
NNT to prevent 1 event for 5 years was comparable to that 
reported in AFCAPS/TexCAPS, and less than those accepted 
for the use of diuretics or beta-blockers in treating hyperten-
sion for primary prevention. Another point emphasized was 
that 80% of individuals who developed diabetes occurred 
among those participants who had impaired glucose tolerance 
at baseline, but those patients also benefited from treatment 
in terms of end points. Last, reduction of both LDL and CRP 
levels was especially successful, and dual targeting may sim-
plify decisions to treat. Another detailed analysis of absolute 
risk reductions and consequent NNT within the JUPITER 
trial, including alternative statin regimens, concluded that 
NNT values are acceptable.311
Yang et al,312 using a JUPITER-eligible cohort from the Ath-
erosclerosis Risk in Communities (ARIC) Study (men $ 50, 
women $ 60, CRP $ 2 mg/L, LDL , 130 mg/dL), sought to 
determine if the absolute event rates and risk reduction seen 
in JUPITER would persist for a period longer than the 1.9 
year follow-up. Of their JUPITER-eligible participants, there 
was an absolute CVD risk of ≈10.9% over a mean follow-up 
of 6.9 years, or 1.57% per year. Applying JUPITER HRs 
to this group generated an NNT of 38 over 5 years and 26 
over 6.9 years. They concluded that the use of age and CRP 
level was a convenient method of identifying higher risk 
individuals.
Vaccarino and coworkers313 noted the absolute risk reduc-
tion of 0.59% per year for the primary end point required 
169 persons to be treated for 1 year to prevent a single com-
bination of events. To prevent a major coronary event, such 
as an MI, 500 patients needed to be treated for 1 year for a 
single event. An estimate of a drug cost for rosuvastatin of 
US$638,750 per year was made to prevent 1 event, and for 
a generic statin, US$24,000 per year. In their view, adding 
CRP screening costs of US$62,500, and then for additional 
liver function, glucose, and HbA1c monitoring, a total of over 
US$137,000 was reached per year for each event prevented. 
These authors suggested that the funds instead be invested 
in effective, proven population-based strategies to lower 
risk, as discussed elsewhere.314–316 In general, the costs per 
life year for lifetime treatment using simvastatin vary from 
US$2500 to US$10,990, depending on age and risk.317 Accad 
and Fred318 also opined that, according to their calculations, 
treatment of 95 individuals for 2 years to avoid 1 event is not 
a sufficient reward for the person with a high CRP level, but 
may be acceptable on a population level. On the other hand, 
Slejko et al269 maintained that statin therapy in   JUPITER 
patients is cost-effective, at a cost of US$40,457 per qual-
ity adjusted life-year, below the customary threshold of 
US$50,000. MacDonald271 estimated that treating JUPITER-
eligible individuals with rosuvastatin is highly cost-effective, 
but is a function of the initial FRS.
Kappagoda and Amsterdam319 reviewed treatment in 
the JUPITER study according to traditional risk factors and 
guidelines, and their calculations showed the following. 
Baseline characteristics of the participants revealed 2225 in 
each group with systolic blood pressures over 145 mm Hg. 
Treating these elevations would have lowered the number 
of strokes by 12 over the duration of the study. Similarly, 
by treating those individuals with LDL . 119 mg/dL and 
HDL , 40 mg/dL (about 25% of the subjects), and over-
weight individuals (.50%) with weight loss, and eliminating 
tobacco use in the 16% who smoked, along with adminis-
tering evidence-based aspirin prophylaxis in men for CHD 
prevention, and in women for stroke prevention, meaningful Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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benefits would have changed outcomes. Aspirin alone could 
potentially have prevented 72 of the 99 MIs that occurred 
during the course of the JUPITER trial. Finally, since the 
baseline median HbA1c was 5.7% (reference range 4.8% to 
5.9%), 2225 individuals in each group had levels .5.9%, 
suggesting that close to 25% of the entire JUPITER popula-
tion met this criterion for diabetes. These authors suggested 
that because guidelines for care were not strictly followed, 
a spuriously high event rate may have caused an appear-
ance of higher benefit from statin therapy. The event rate, 
however, was similar in the ARIC profile cohort that was 
JUPITER-eligible,312 although smaller, which would argue 
against this view.
A most significant dual target analysis of the JUPITER 
study evaluated the effects of rosuvastatin 20 mg versus pla-
cebo on the prespecified end points according to on-treatment 
values of LDL (,70 or $70 mg/dL) and CRP (,2 mg/L, 
or ,1 mg/L).320 Compared to placebo, those in the treat-
ment group who achieved an LDL , 70 mg/dL had a 55% 
reduction in vascular events per 100-person years (Table 4). 
Those who achieved CRP , 2 mg/L had a 62% reduction 
in events. Among those who reached dual reductions, there 
was a 65% reduction in events compared to a 33% reduc-
tion in those who achieved one or neither target. Those who 
reached an LDL , 70 mg/dL and a CRP , 1 mg/L enjoyed 
a 79% reduction in events (Table 5). Treatment CRP levels 
predicted the event rate no matter what lipid end point was 
used, including the ratio of aopB/aopA-1. Therefore, regard-
less of the lipid profile, the lower the CRP, the better was the 
prognosis. An editorial concluded that JUPITER provided 
“key experimental data” that inflammation mediated the 
benefits of rosuvastatin, but mused at the prospect of compar-
ing the absolute risk reduction of statins with the effects of 
weight loss and regular exercise, remarking that such a study 
is unlikely,321 both for lack of funding and interest. Many of 
the pleiotropic effects of rosuvastatin are anti-inflammatory, 
and a catalog of those actions – significant improvement in 
endothelial function, immune responses, plaque stabilization, 
vascular remodeling, and oxidative stress – and antithrom-
botic actions322 further underpins the observation that target-
ing CRP is worthwhile and clinically rewarding.
The use of statins in women, particularly for primary 
prevention, has been heavily debated.323–325 Mora and cowork-
ers326 performed a specific gender-specific analysis from 
JUPITER using rosuvastatin 20 mg or placebo employing 
the criteria mentioned above. Focusing only on 6801 female 
participants in JUPITER, treatment significantly lowered 
the relative risk of the primary end point, composite of MI, 
stroke, revascularization, hospitalization for unstable angina, 
and death from cardiovascular causes, by 46%. The great-
est benefit was seen for revascularization, associated with a 
treatment-related reduction of 76% compared to placebo. A 
meta-analysis of 5 studies reporting sex-specific outcomes was 
also undertaken. Absolute CVD rates per 100 person-years 
in JUPITER women were lower than for men, with similar 
relative risk reductions between the sexes. A total of 13,154 
women were included from primary prevention trials, and a 
significant reduction in primary CVD events with statins by 
one-third was found (relative risk 0.63; 95% CI 0.49 to 0.82; 
P , 0.001). These results were similar to prior results in men, 
and also to findings for secondary prevention in women. It was 
postulated that the greater numbers enrolled allowed JUPITER 
to demonstrate the benefit.327 CRP was noted as a tighter 
predictor of events in women than in men, along with the cor-
relation between the degrees of CRP lowering and associated 
clinical benefit. These authors concluded that while CRP level 
as an independent predictor of events remains controversial, 
CRP is accepted as a marker which may be involved in the 
atherogenic process.237
The FDA approved rosuvastatin for primary prevention on 
February 9, 2010, following a 12-4 vote in a panel 2 months 
before, which only seemed to flare the ongoing controversy 
about its use in “healthy” individuals.328 The new indication was 
for men $ 50 years and women $ 60 years with fasting LDL 
Table 4 Cardiovascular events fell based on LDL cholesterol and 
on hs-CRP levels ,2 mg/L
LDL cholesterol (mg/dL) 
and hs-CRP (mg/L) values
Event rate Hazard ratio  
(95% CI)
$70 and $2 1.11 1.06 (0.72–1.55)
$70 and ,2 0.54 0.42 (0.18–0.94)
,70 and $2 0.62 0.53 (0.38–0.74)
,70 and ,2 0.38 0.35 (0.23–0.54)
$70 or $2 0.38 0.64 (0.49–0.84)
Abbreviations: CI, confidence interval; LDL, low-density lipoprotein; hs-CRP, 
high CRP.
Table 5 Cardiovascular events fell based on LDL cholesterol and 
on hs-CRP levels ,1 mg/L
LDL cholesterol (mg/dL) 
and hs-CRP (mg/L) values
Event rate Hazard ratio  
(95% CI)
$70 and $1 0.95 0.89 (0.62–1.28)
$70 and ,1 0.64 0.46 (0.11–1.85)
,70 and $1 0.56 0.49 (0.37–0.66)
,70 and ,1 0.24 0.21 (0.09–0.51)
$70 or $1 0.67 0.59 (0.46–0.75)
Abbreviations: CI, confidence interval; LDL, low-density lipoprotein; hs-CRP, 
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# 130 mg/dL, CRP $ 2.0 mg/L,   triglycerides #500 mg/dL, no 
diagnosed CVD, and at least 1 additional CVD risk factor.
Summary of articles in the Archives  
of Internal Medicine
Kaul and collaborators329 challenged 3 aspects of the JUPI-
TER study, asking (a) does CRP predict risk and treatment 
response? (b) did early stoppage of JUPITER unduly raise 
the benefit? and (c) what about guideline recommenda-
tions? First, they believed that the predictive value of 
1.35%, although positive in JUPITER (241 events in 17,802 
patients), was weak, and basically that treatment decisions 
should not be stratified using CRP values because there was 
no low-CRP, low-LDL control arm for comparison. This 
arm was excluded in the design of JUPITER because of the 
prior post-hoc analysis of AFCAPS/TexCAPS showing no 
benefit in a group with low CRP.246,330 The JUPITER authors 
hypothesized, with considerable supporting evidence from 
other investigators and studies outlined above, that high CRP 
levels reflected increased risk, and treatment with rosuvas-
tatin addressed that component over and above any LDL 
lowering.310 A fair consensus from the many commentaries 
and blogs would be that a high level of CRP does have clinical 
utility, portends an otherwise poorer prognosis, but a normal 
CRP value does not assure low risk.
Second, the early termination of JUPITER may have led 
to a somewhat higher benefit than would have been observed 
from a longer study period. Compared to other statin studies 
in primary prevention, JUPITER reported unexpectedly larger 
reductions in ischemic end points including mortality. Studies 
terminated prematurely in other trials are known to exagger-
ate benefits, which regresses to the mean when follow-up 
is longer.331–334 A large systematic review reported that for 
interventions showing a 20% improvement in completed tri-
als, stopping them early might double the apparent benefit.332 
It is true that other studies used less potent statins, but a rapid 
mortality benefit within this period is exceptional. Details pro-
vided subsequent to JUPITER concerning the circumstances 
of the early termination did not reflect any intent to exaggerate 
the positive results. Kaul agreed that rosuvastatin benefits did 
occur in JUPITER, although perhaps were increased by the 
early stoppage of the study.330 The pathology in the CORONA 
and AURORA populations was sufficiently different from 
JUPITER to make a comparison of results difficult.
Third, Kaul et al329 question the conclusion that high CRP 
levels predict preferential improved response in JUPITER, 
based on an FDA analysis showing, essentially, that treatment 
effect of statins was not proportional to the degree of elevation 
in CRP.335 This conclusion was based on a stratification of FRS 
risk scores according to the CRP level. In addition, however, 
data presented in Tables 4 and 5 show a clear relationship 
between low CRP values and good prognosis.321 Kaul et al 
concluded that 44% risk reductions in JUPITER-eligible 
patients in the population will not be typically attained if CRP-
guided rosuvastatin therapy is used. Their second conclusion, 
with which everyone agrees, is that control of risk factors 
with lifestyle modification trumps pharmacologic interven-
tion in primary prevention. The third conclusion advises that 
if patients do not change their lifestyle, then statins may be 
used. In practice, since ≈95% of individuals will fall into this 
category, ultimately most patients will receive statins, simply 
because there are no comparable alternatives.
De Lorgeril et al336,337 maintained that a) there was a 
discrepancy between the reduction in mortality between end 
point subgroups; b) cardiovascular mortality was 5% to 18% 
compared with total mortality and the expected rate is about 
40%; c) the case-fatality rate of MI was low compared to an 
expected figure of 50%; the case mortality rate in the placebo 
group was 8.8% compared to 29% in the rosuvastatin group; 
d) no sudden cardiac death was reported in JUPITER; and 
e) bias may have been introduced because of conflicts of 
interest and commercial sponsorship. These analysts believed 
that there was no significant difference in cardiovascular 
mortality between the two groups in JUPITER. Last, they 
lamented the secondary end point and subgroup analyses 
published concerning benefit in preventing venous throm-
boembolic disease,338 efficacy in women,326 lower stages of 
chronic renal disease,339 and in the elderly340 because they 
shared the limitations of the original study.
Several of the earnest concerns summarized in the 
papers by Kaul329 and de Lorgeril336 have been addressed 
by investigators other than JUPITER, and have also been 
answered in part by subanalyses and refinements pre-
sented by the JUPITER authors during the past 2 years. 
For instance, the association of high levels of CRP with 
vascular risk has considerable supportive evidence from 
multiple sources, and the recent meta-analysis of 54 pro-
spective studies by the Emerging Risk Factors Collabora-
tion confirmed this relationship.237 Specifically, the adjusted 
risk associated with a 1-standard deviation increase in CRP 
(HR 1.4; 95% CI 1.3 to 1.5) compared quite favorably 
with that associated with a similar increase in cholesterol   
(HR 1.2; 95% CI 1.1 to 1.3).
A closer evaluation of the relationship between base-
line CRP measurements and cardiovascular risk is also 
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ordinal variable and as a threshold variable, relative risk 
reduction after rosuvastatin therapy was similar maintained 
across the entry levels of CRP. Absolute risk reductions 
therefore were greatest in the patients with the highest 
entry levels of CRP. Independent corroboration of these 
data is found in the ARIC study312 in which groups with 
similar FRS and LDL levels had higher vascular risk when 
the CRP was elevated, compared to counterparts with low 
CRP values.
JUPITER findings incorporated  
into the Canadian Cardiovascular  
Society guidelines
The Canadian Cardiovascular Society acknowledged 
JUPITER findings in their guidelines and recommended 
measurement of CRP in JUPITER-eligible individuals at 
“intermediate risk” as a step toward prophylactic statin 
treatment.257 The Society extended recommendations from 
the CDC in which CRP levels were considered an adjunct 
to risk assessment in healthy persons with an FRS between 
5%–20%, ie, at intermediate risk.341 In JUPITER, the event 
rate in the placebo group was greater than in AFCAPS/
TexCAPS study, and most individuals had an FRS between 
5% and 20%. Analysis of JUPITER trial data stratified 
according to both the Framingham and Reynolds 10-year 
risk scores confirmed that treatment of JUPITER-eligible 
men and women in the “intermediate” categories (5% to 
10% and 10% to 20% 10-year risk) significantly reduced 
cardiovascular events.342 In the 5% to 10% FRS category 
who were treated, HR was 0.55 (95% CI 0.36 to 0.84; 
5-year NNT = 40, P = 0.005) (Table 6). In the 11% to 20% 
risk category, HR was 0.51 (95% CI 0.39 to 0.68, 5-year 
NNT = 18; P , 0.0001).
Using the FRS, no significant benefit occurred in the 
groups with either low or very high risk. The Reynolds risk 
score reclassified more individuals into these two categories, 
low (,5%) and high (.20%), and rosuvastatin did produce 
a benefit in those at highest risk. Since the FRS underesti-
mates risk in women, and frequently women do not have 
FRS . 10%, they may not be considered for treatment under 
current guidelines. Using CRP $ 2 mg/L as part of JUPITER 
criteria would include almost 7000 of such women who could 
potentially benefit from rosuvastatin therapy. This number 
becomes considerable in view of the growing awareness of 
serious gender disparities in CHD treatment.343
Summary of response  
of JUPiTeR authors
Ridker and Glynn330,344 and Ridker345 responded to the four major 
issues raised by De Lorgeril et al,336 namely a potential deficiency 
in trial design and execution; early termination of the study was 
inappropriate and/or favored to exaggerate benefit; inconsisten-
cies existed concerning mortality, statin treatment and CRP; and 
pharmaceutical company sponsorship played a significant part 
in the positive outcomes, as summarized below.
JUPiTeR study design
The study was logically designed, participant follow-up was 
careful and full, end point adjudication was rigorous, and 
followed a pre-specified analysis plan.
Table 6 Event rates and hazard ratios for the primary end point correlated with estimated 10-year Framingham and Reynolds risk 
scores at baseline
Risk level  Event rate/100-person years, 
rosuvastatin 20 mg group
Event rate/100-person years,  
placebo group
Hazard ratio (95% CI) 
Framingham 10-year risk score 
,5% (n = 2791, 173 men, 2618 women) 0.22 0.34  0.64 (0.23–1.81)
5%–10% (n = 6091, 2525 women, 3566 men) 0.50 0.92 0.55 (0.36–0.84) 
5-year NNT = 40a
11%–20% (n = 7340,1404 women, 5936 men) 0.95 1.84 0.51 (0.39–0.68) 
5-year NNT = 18b
.20% (n = 1555, 242 women, 1313 men) 1.72 2.41 0.70 (0.43–1.14)
Reynolds 10-year risk score
,5% (n = 3583, 944 men, 2639 women) 0.26 0.41 0.62 (0.27–1.43)
5%–10% (n = 6436, 2651 women, 3785 men) 0.44 1.00 0.45 (0.29–0.68)
11%–20% (n = 5040, 1151 women, 3889 men) 1.07 1.65 0.65 (0.47–0.90)
.20% (n = 2651, 327 women, 2324 men) 1.55 2.84 0.55 (0.38–0.80)
Notes: aCorresponds to estimated absolute risk difference between treated and placebo groups at 5 year of ≈2.5 events/100 person-years; bCorresponds to estimated 
absolute risk difference between treated and placebo groups at 5 year of ≈5.7 events/100 person-years.
Abbreviations: CI, confidence interval; NNT, number needed to treat.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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early termination of the trial
The details concerning the charter between the investigators 
and members of the independent Monitoring Board that 
decided to end the trial early were described. The decision 
to do so followed that agreement and was just and proper. 
The investigators reiterated that any overestimate of relative 
risk reduction involved would have been small, estimated 
by an FDA statistical analysis at #1%.346 Since the benefit 
was highly significant at 44% reduction in relative risk for 
the primary end point, there would be no clinically signifi-
cant change in outcome interpretation. Simulation studies 
indicated that stopping the study early under similar circum-
stances produced valid treatment results.347,348
The benefits of rosuvastatin therapy in JUPITER were 
much larger than those reported in earlier statin trials. How-
ever, the relative risk lowering in JUPITER was similar to 
the analysis of a JUPITER-eligible cohort in the AFCAPS/ 
TexCAPS study previously reported.246 In addition, earlier 
statin trials showed that a 1% fall in LDL level corresponded 
to a 1% reduction in relative risk. This was approximately 
the same in JUPITER, since rosuvastatin lowered LDL by 
50%, and the resulting fall in relative risk was about the 
same magnitude.
A sequential review of the benefit of rosuvastatin treat-
ment throughout JUPITER demonstrates that the differences 
between treatment and placebo groups increased steadily as 
the study progressed, rather than decreased.344
Inconsistencies in case-fatality rate
Instances of events and deaths required proof to be clas-
sified as cardiovascular, and many out-of-hospital deaths 
were termed “noncardiovascular” in the absence of such 
proof. There were 35 deaths from CVD in the treated group 
and 43 in the placebo group. The death rates for SCD were 
16 in the rosuvastatin group versus 25 in the placebo group, 
suggesting a larger beneficial effect in the SCD component 
than was reported for total and cardiovascular mortality 
(Table 7).
Influence of the sponsor-affected outcomes
The sponsor, AstraZeneca, had no access to the data or any 
role in the analyses or manuscript writing.
Side effects
Pharmaceuticals nearly always have side effects, but most 
do not rise to clinical significance. Adverse events associ-
ated with statins have been exceptionally well studied. As 
the most potent member of its class, rosuvastatin is also 
associated with unwanted events. Molecular mechanisms 
have yet to be fully characterized. No one study imposes 
use of drugs on any patient – use is weighed on the ratio of 
potential benefits with respect to risks, first by the FDA, then 
subsequently by the prescribing physician. A vast amount 
of clinical evidence suggests that, for statins in general, and 
rosuvastatin in particular, this ratio is large.
JUPITER reported a rise in the number of cases of dia-
betes in the treatment group, amounting to 270 events, or 
about a 25% increased risk of developing diabetes. In about 
1.4% of prescriptions, rosuvastatin has to be discontinued 
due to adverse reactions, with the Package Insert quoting 
the incidence of myalgia at 3.1%, abdominal discomfort, 
2.6%, asthenia, 2.5%, and nausea at 2.2%. The frequency 
of overt myotoxicity, with diagnostic elevations in creatine 
kinase (CK) 10-fold higher than the upper limit of normal 
and requiring inpatient care, is in the order of 0.4 per 10,000 
person-years.349,350 Less severe myalgia, however, may be 
responsible for discontinuing statins in 5% to 10% of statin 
users.351,352 Both myotoxicity and an increase in the incidence 
Table 7 Components of the primary end point reached in the JUPITER study
End point Rosuvastatin group Placebo group Hazard ratio 95% CI P value
Primary end point 142 251 0.56 0.46–0.69 ,0.00001
Nonfatal Mi 22 62 0.35 0.22–0.58 ,0.00001
Any Mi 31 68 0.46 0.30–0.70 ,0.0002
Nonfatal stroke 30 58 0.52 0.33–0.80 0.003
Any stroke 33 64 0.52 0.34–0.79 0.002
Revascularization or  
Unstable angina
76 143 0.53 0.40–0.70 ,0.00001
MI, stroke, CV death 83 157 0.53 0.40–0.69 ,0.00001
Total mortality 198 247 0.80 0.67–0.97 0.02
CV death (verified) 35 43 0.82 0.52–1.27 0.37
Sudden death 16 25 0.64 0.34–1.20 0.16
Abbreviations: CI, confidence interval; CV, cardiovascular; MI, myocardial infarction.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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of diabetes, as noted in JUPITER, are currently of greatest 
interest.
Statins raise incidence of diabetes
In a study of 345,417 men, Sukhija et al353 reported that a 
decrease in insulin sensitivity was a class effect of statin drugs, 
and found that the change in fasting plasma glucose level 
in nondiabetic statin users was 7 mg/dL (versus 5 mg/dL in 
patients not using statins; P , 0.0001), and in diabetic statin 
users, the rise was 39 mg/dL (versus 32 mg/dL in patients not 
using statins; P , 0.0001). The effect has subsequently been 
confirmed for atorvastatin354 and for rosuvastatin,355 which pro-
duced a dose-dependent rise in insulin resistance. Using data 
from the Cholesterol Treatment Trialists’ Collaborators,356 
Sattar and colleagues357 conducted a meta-analysis of 13 
randomized statin trials and studied the incidence of diabetes 
among 91,140 participants. Statin therapy was associated with 
a 9% increased risk for diabetes, translating to 1 extra case of 
diabetes per 255 patients treated over 4 years. Absolute risk 
was low, at 1 case per 1000 patient-years of treatment. Dur-
ing those 4 years, however, 5.4 MIs or cardiovascular deaths 
and 5.4 coronary revascularizations and strokes would be 
prevented, amounting to an overall benefit of 9:1 events. Their 
analysis also indicated that lowering glucose tolerance was a 
class effect of statins, in agreement with a review of several 
statin trials prior to   JUPITER.310 Baker et al358 systematically 
reviewed 16 studies and determined there was no class effect 
of statins upon glucose tolerance in patients without diabetes, 
and that differences between statins may have accounted for 
prior findings.
Some side effects of statins are obligatory consequences 
of HMGR inhibition of the mevalonate pathway used 
for cholesterol synthesis (Figure 2), and are molecularly 
unavoidable, extending throughout the metabolome. Among 
the intermediate products of this pathway are the 15-carbon 
farnesyl pyrophosphate and 20-carbon geranylgeranyl 
pyrophosphate molecules, used to add an isoprenoid group 
to over 100 signaling proteins in a fundamental post-
translational modification known as prenylation.359 This 
addition of an isoprenoid group is necessary for function 
of small Rho-family GTPases such as Rac, Rho, and Rab. 
Some of these GTPases serve as molecular switches, and 
others are involved in intracellular membrane trafficking, 
using the lipophilic prenyl group to anchor in membranes.360 
Many desirable pleiotropic actions of statins, such as the 
antioxidant, anti-inflammatory, and antiproliferative prop-
erties361–363 may be related to decreased ability to prenylate 
signaling molecules. Inhibition of Rho and its downstream 
target Rho kinase (ROCK) function is especially important, 
since elevated ROCK activity may occur in association with 
elevated CRP levels364 and contribute to atherosclerosis.365,366 
Less desirable consequences of HMGR inhibition may 
arise from deficiencies in downstream metabolites of the 
mevalonate pathway such as ubiquinone and dolichol, 
which are, respectively, ignored and largely unknown. 
Dolichol, a family of linear polyisoprenols containing 16 to 
22 isoprene units, are carriers involved in N-glycosylation 
of nascent polypeptides, and serve as sites for assembly of 
oligosaccharides during the formation of glycoproteins, 
ensuring the membrane fluidity and permeability required 
for glycoprotein maturation and secretion.
There are several signaling steps between the insulin 
receptor and translocation of the glucose transporter GLUT4 
from specialized intracellular compartments to the plasma 
membrane. Individual statins may have different effects 
upon these steps, and which of them predominate may 
account for differences on overall glucose tolerance.367 
Thus, in one preparation, atorvastatin may improve glucose 
tolerance, possibly by lowering membrane cholesterol 
content368 yet in another report atorvastatin appeared to 
attenuate the expression of GLUT-4 in adipocytes to lower 
glucose tolerance.369 In addition, there may be differential 
effects of statins upon levels of adiponectin, leptin, and 
other inflammatory mediators that affect glucose intoler-
ance. Differences in lipophilicity among the statins may 
contribute both to the effects on insulin sensitivity and 
myotoxicity. Pravastatin, which improves glucose toler-
ance when compared with atorvastatin, has a relatively 
favorable effect on beta-cell function.370,371 It has been 
suggested that pravastatin, hydrophilic but forming weak 
steric interactions with HMGR, has limited ability to block 
the mevalonate pathway in cells outside the liver.358 Sim-
vastatin, which worsens glucose tolerance, has a greater 
affinity for cell membranes due to its lipophilicity, and may 
block L-type calcium channels, interfering with glucose-
induced cytosolic calcium signaling and insulin secretion 
in beta cells.372 Another possible explanation for statin-
induced glucose intolerance includes dysfunctional insulin 
receptors and/or insulin-like growth factor receptors as a 
result of impaired glycosylation (see above).373 Finally, by 
upregulating hepatic LDL receptors, a greater number of 
triglyceride-rich particles returning to the liver may induce 
hepatic insulin resistance.374
In view of the large reduction in major vascular events 
associated with use of statins in diabetics,356 the small 
increase in diabetes discussed above has not changed clinical Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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practice,375 and further work is needed to delineate its clini-
cal significance.
Statin-induced myopathy
Statin myotoxicity is a major concern of practitioners; part 
of the reluctance to titrate LDL levels down to guideline 
targets is a fear of myopathy. Although this phenomenon 
has received enormous attention from researchers, clinicians, 
the lay press, and on the internet, its mechanism and optimal 
management remain uncertain. The spectrum of myopathy 
or myotoxicity includes myalgia (muscle ache or weakness 
without CK elevation), myositis (muscle symptoms with 
raised CK levels), and rhabdomyolysis (symptoms with CK 
over the upper limit of normal by a factor of at least 10).376 
Myalgia is noted in randomized statin trials in the order 
of ,3%, compared to the incidence in outpatient lipid clin-
ics, which varies between 5% and 10%.377 Underreporting is 
commonly assumed, but individuals with predisposing con-
ditions are carefully screened, and many randomized   trials 
include a run-in period, then fail to randomize candidates 
with myopathic symptoms.
During vigorous exercise, the phenomenon is accentu-
ated, raising the reported incidence of myalgia up to 25%.378 
Statin intolerance among athletes is well known. Factors that 
predispose to myopathy are increasing age, female gender, 
hepatic or renal disease, diabetes, polypharmacy, and any 
condition that diminishes muscle reserve (small frame, 
frailty, sarcopenia), or causes muscle pathology, including 
hypothyroidism or hyperthyroidism, metabolic muscle dis-
ease, polymyalgia rheumatica, autoimmune diseases with 
myositis, postoperative status, hypovitaminosis D, chronic 
alcohol use, and others.
Some adverse reactions may be minimized by avoiding 
negative drug–drug interactions. As mentioned above, since 
rosuvastatin is not eliminated through the CYP3A4 pathway, 
only minimally metabolized by the CYP2C9 enzyme, and 
does not interfere with P-gp, drugs that inhibit OATP1B1, 
a transporter that facilitates rosuvastatin uptake in the liver, 
may clinically be more important offenders than cytochrome 
P450 inhibitors or substrates. Common drugs usually 
mentioned that may raise the likelihood of myotoxicity 
are cyclosporine, gemfibrozil, itraconazole, ketoconazole, 
fluconazole, lopinavir/rotinavir, atazanavir/ritonavir, fosam-
prenavir/ritonavir, warfarin, and amiodarone. Some of the 
quantitative effects of coadministered drugs are summarized 
in Tables 8 and 9. As noted in Table 9, digoxin coadminis-
tered with rosuvastatin only raises the AUC 4%, reflecting 
the statin is not a P-gp substrate. Genetic polymorphism 
within SLCO1B1, the gene that encodes OATP1B1, produces 
a variant which increases susceptibility to statin-induced 
myopathy.379
Since statins affect many different molecules and 
signaling systems, the mechanism of statin myopathy also 
remains uncertain. A relationship to a deficiency of preny-
lating moieties, farnesyl pyrophosphate and geranylgeranyl 
pyrophosphate, is again likely. Inability to prenylate seleno-
proteins, dolichols, and small GTPases Rho, Ras, and Rac 
is believed to disturb intracellular trafficking of proteins 
between membranes needed for muscle growth and repair. 
Statins specifically activate mechanisms that lead to muscle 
atrophy in a number of circumstances, mediated by overex-
pression of atrogin-1, a muscle-specific E3 ubiquitin ligase in 
the ubiquitin proteasome proteolytic pathway.380–382 Induction 
of atrogin-1 appears to be significant in the pathogenesis of 
statin myopathy, but is by no means the only mechanism. 
Experimental overexpression of peroxisome proliferator-
  activated receptor-gamma coactivator-1α (PPARγ coacti-
vator 1α or PGC-1α), coactivator of many transcription 
factors and a regulator of mitochondrial number and func-
tion, attenuates statin-induced atrogin-1 expression, protects 
against statin myotoxicity, and may lead to a therapeutic   
target.
Skeletal muscle expresses drug transporters such as 
OATP2B1, high-affinity uptake transporters for both ator-
vastatin and rosuvastatin.383 A number of efflux transporters, 
multidrug-resistance-associated proteins 1, 4, and 5, are 
also expressed on the sarcolemmal membrane of skeletal 
muscle. Susceptibility to myotoxicity may depend not only 
on the serum concentration of rosuvastatin, but also locally 
on the balance between activities of muscle fiber uptake and 
efflux transporters. For example, in one experimental model, 
probenecid, which inhibits efflux transporter MRP1, raised 
myocyte rosuvastatin levels and promoted myotoxicity.384
Lipophilic statins, such as lovastatin or simvastatin, 
inhibit protein synthesis in skeletal myotubules to a greater 
extent than hydrophilic statins, such as pravastatin.385 
Statins in higher doses may decrease the ability of muscle 
progenitor cells (satellite cells) to repair and regenerate 
skeletal   muscle.386 Only in part because they severely reduce 
ubiquinone (coenzyme Q10) levels, statins are associated 
with multiple defects in muscle mitochondrial anatomy 
and function.387 Lower mitochondrial volume, mitochon-
drial DNA loss, reduction in mitochondrial membrane 
potential, inefficient oxidative phosphorylation, anatomical 
fractionation, leakage of pro-apoptotic chemicals through 
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reported. Apoptosis of muscle cells – direct myotoxicity – has 
been described after acute statin exposure.383,388 Intracellu-
lar calcium overload and activation of caspase-3 to initiate 
apoptosis is yet another proposed mechanism.389 Dolichol is 
needed for synthesis of α-dystroglycan, a major protein in 
the skeletal muscle dystrophin–glycoprotein complex, and 
deficiencies have been linked to muscle dysfunction. Finally, 
some evidence also implicates immune involvement, which 
may persist after statin therapy is discontinued.390,391 Four 
detailed, well-referenced recent reviews of statin myotoxic-
ity are available.392–395
In summary, it appears that the side effects of statins are 
just as multimechanistic, or “pleiotropic”, as the beneficial 
actions. Despite these seemingly complex biochemical 
effects, in practice, the incidence of myopathy and glucose 
intolerance is far outweighed by the overall benefits of statins 
in general, and rosuvastatin in particular.396,397 Most serious 
events may be averted with careful monitoring and avoidance 
of drug interactions, but individual and genetic susceptibility 
can unfortunately not yet be predicted clinically. The over-
whelming majority of patients tolerate rosuvastatin well. In 
JUPITER, there were no significant differences in myotoxic-
ity between treatment and control groups.
Conclusion
The challenge of a rising sea of cardiovascular risk, threaten-
ing to reverse improved coronary death rates, is immense. 
The reality is that few individuals will sustain the necessary 
Table 8 effect of coadministered drugs on rosuvastatin systemic exposure
Coadministered drug and dosing 
regimen 
Rosuvastatin 
Dose (mg)a Change in AUCb Change in Cmax
b
Cyclosporine – stable dose required  
(75–200 mg twice daily)
10 mg daily for 
10 days
↑ 7-foldc ↑ 11-foldc
Gemfibrozil 600 mg twice daily for 7 days 80 mg ↑ 1.9-foldc ↑ 2.2-foldc
Lopinavir/ritonavir combination 400 mg/100 mg 
twice daily for 10 days
20 mg daily for 
7 days
↑ 2-foldc ↑ 5-foldc
Atazanavir/ritonavir combination 
300 mg/100 mg daily for 7 days
10 mg ↑ 3-foldc ↑ 7-foldc
Tipranavir/ritonavir combination 500 mg/200 mg  
twice daily for 11 days
10 mg ↑ 26% ↑ 2-fold
Fosamprenavir/ritonavir 700 mg/100 mg twice 
daily for 7 days
10 mg ↑ 8% ↑ 45%
Fenofibrate 67 mg 3 times daily for 7 days 10 mg ↑ 7% ↑ 21%
Aluminum and magnesium hydroxide 
combination antacid, administered 
simultaneously
40 mg ↓ 54%c ↓ 50%c
The above, administered 2 hours apart 40 mg ↓ 22% ↓ 16%
erythromycin 500 mg 4 times daily for 7 days 80 mg ↓ 20% ↓ 31%
Ketoconazole 200 mg twice daily for 7 days 80 mg ↑ 2% ↓ 5%
Itraconazole 200 mg daily for 5 days 10 mg  
80 mg
↑ 39% 
↑ 28%
↑ 36% 
↑ 15%
Fluconazole 200 mg daily for 11 days 80 mg ↑ 14% ↑ 9%
Notes: aSingle dose unless otherwise noted; bMean ratio (with/without coadministered drug and no change = 1-fold) or % change (with/without coadministered drug and no 
change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively; cClinically significant.
Abbreviations: AUC, area under the plasma concentration-time curve; Cmax, peak plasma concentration.
Table 9 effect of rosuvastatin coadministration with warfarin, digoxin, and an oral contraceptive
Rosuvastatin dosage regimen  Coadministered drug 
Name and dose Change in AUC Change in Cmax
40 mg daily for 10 days warfarin 25 mg, single dose R-Warfarin ↑ 4%  
S-Warfarin ↑ 6%
R-Warfarin ↓ 1%  
S-Warfarin 0%
40 mg daily for 12 days Digoxin 0.5 mg, single dose ↑ 4% ↑ 4%
40 mg daily for 28 days Oral contraceptive (EE 0.035 mg 
and NG 0.180, 0.215, and 0.250 mg) 
daily for 21 days
ee ↑ 26% 
NG ↑ 34%
ee ↑ 25% 
NG ↑ 23%
Abbreviations: AUC, area under the plasma concentration-time curve; Cmax, peak plasma concentration; EE, ethinyl estradiol; NG, norgestrel; R-warfarin and S-warfarin, 
referring to the stereoisomers.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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lifestyle and behavioral changes to lower their risk, and this 
is amply reflected by the dismal success in weight control. 
Obesity drives the dual epidemics of diabetes and CHD. 
Primary prevention, sometimes regarded as an illusion, is 
only effective if it is done early and intensively. When life-
style modification fails, reduction of elevated risk factors 
through pharmacological means is imperative, because by the 
time they are evident, atherosclerotic processes are already 
advanced. If we are to stem the tide, simply waiting for a 
cardiovascular event or diagnosis will no longer suffice.
Asymptomatic individuals randomized in the JUPITER 
study, many similar to those in the general population, bore 
a considerable cardiovascular burden, even though they were 
free from a formal diagnosis of heart disease, diabetes and 
dyslipidemia. Studies other than JUPITER confirm that higher 
values of CRP are associated with greater cardiovascular risk, 
which may assist in the decision of whether to treat or not. With 
the FDA approval for the use of rosuvastatin in JUPITER-
eligible patients with at least one additional cardiovascular risk 
factor, an additional choice became available to clinicians.
The prevalence of metabolic syndrome in JUPITER par-
ticipants was about the same as in US adults at the present 
time. JUPITER demonstrated that within this population, 
those persons with elevations in CRP levels benefited from 
rosuvastatin therapy. While, as mentioned, some critics, 
observing that 41% of JUPITER participants had metabolic 
syndrome, suggested this diminished the value of the study. 
However, one can argue that the opposite was true, in that 
JUPITER demonstrated that rosuvastatin therapy in this syn-
drome, when CRP was elevated, was effective therapy. The 
prevalence of metabolic syndrome more closely follows the 
rise in level of visceral adiposity within the population, now 
averaging 53%.398 At the moment, the highest prevalence of 
metabolic syndrome reported in an US subpopulation also 
stands at 53%.127 The evidence that inflammation plays a 
critical role in the pathogenesis of components of metabolic 
syndrome is of high quality.198,199 A recent systematic review 
and meta-analysis of 87 studies involving 951,083 patients 
found that metabolic syndrome is associated with a 2-fold 
increase in risk of CVD, cardiovascular mortality, and stroke, 
and a 1.5-fold rise in all-cause mortality.399
DeMazumder et al400 noted that the use of global risk 
assessment tools may result in denial of statin therapy 
to individuals at low risk when current guidelines are 
employed, while others with a high absolute risk may not 
benefit from statin therapy. These authors therefore sug-
gested that statin therapy might be better allocated on the 
basis of randomized trial evidence rather than global risk 
scores. Nambi and Ballantyne401 proposed a formal protocol 
using the FRS, lifetime risk, and CRP, CIMT, calcium artery 
calcification burden, or genetic risk markers for progressive 
refinement of stratification. CRP measurements may be 
repeated easily, and are less involved than imaging, with 
no radiation exposure.
The reaction to JUPITER, many physicians will agree, 
has been most unusual. The rationale and findings are brack-
eted by many other independent investigations, but the final 
interpretation of the data presented is up to each physician. 
A repeat of JUPITER will probably not occur. The study 
is not perfect, and limitations are clear and well known. 
Controversies in medicine may endure for years without 
resolution. In the individual case, certainly other methods for 
risk stratification, such as CIMT measurement and coronary 
artery calcium score, are available. Processes bringing about 
alterations in each risk factor are different but overlap, and 
the information their changes bring to the physician’s desk 
are complementary, not identical. Eventually a place for 
each will be found in the clinician’s toolbox, but ultimately, 
the individual practitioner has the choice of where to reach 
in his armamentarium, the essence of the “art of medicine”. 
It is encouraging to note that in blog comments written by 
individuals critical of some results and potential applications 
of JUPITER, when presented with specific cases, rosuvasta-
tin is in fact being prescribed for high-risk individuals with 
elevated CRP values in primary prevention, indicating that 
patients’ needs are being valued with higher priority than 
personal views.
Almost all JUPITER-eligible patients who would 
benefit from rosuvastatin have an alternative. Weight 
loss, especially in conjunction with exercise and dietary 
changes, are powerful techniques to lower cardiac risk 
and CRP levels197,213–222 and in fact would be preferred. 
The pervasive condition for which rosuvastatin has been 
found effective in JUPITER differs significantly from other 
diseases. This “illness” of unrecognized cardiovascular risk 
is diffuse, significant, difficult to quantitate, but deadly 
nonetheless. However, it is also largely self-inflicted, 
with a common cause in poor personal lifestyle choices. 
A recurring comment that ostensibly healthy people are 
being subjected to testing and side effects may be, in part, 
rooted in erroneously equating “asymptomatic” with ideal 
cardiovascular health – free of risk factors and a likeli-
hood that none will appear in the near future402 – by the 
public. Perception of risk by patients is commonly inac-
curate, and educational programs have been repeatedly 
recommended.403Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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The broader message of JUPITER is, first, it reminds us 
that the level of cardiovascular risk is currently oppressive, 
and greater than previously recognized when evaluated by 
LDL and global risk scores. Second, physicians must go on 
the offensive, delve into the population, and ferret out the 
risk, rather than wait for the risk to open their office door.
Today the clinician has a much greater amount of 
information and a wider variety of techniques from which 
to choose in order to evaluate individuals for primary pre-
vention. Rosuvastatin will lower risk in JUPITER-eligible 
subpopulations, but also in many others selected differently 
for risk, even if one uses age for stratification, simply because 
the current level of risk is so high. Whatever markers or 
techniques are chosen, a fresh view of preventive care is 
before us, and action is now imperative. New guidelines in 
preparation will hopefully provide even greater direction in 
maximizing returns in primary prevention and improve future 
outcomes in our patients.
Acknowledgment
The author thanks Michelle Delaney for her suggestions, 
computer skills, and astuteness in the preparation of this 
manuscript.
Disclosure
The author states that he has not received any funds or favors 
from any private or public entity, corporation, agency, or 
other source related to this work.
References
1.  USDHHS, National Center for Health Statistics. Second National Health 
and Nutrition Examination Survey (NHANES II). Hyattsville MD: CDC; 
1976–1980.
2.  USDHHS, National Center for Health Statistics. Second National Health 
and Nutrition Examination Survey (Continuous NHANES). Hyattsville 
MD: CDC; 1999–2002.
3.  Young F, Capewell S, Ford ES, Critchley JA. Coronary mortality declines 
in the US between 1980 and 2000. Quantifying the contributions from pri-
mary and secondary prevention. Am J Prev Med. 2010; 39:228–234.
4.  Ford ES, Capewell S. Coronary heart disease mortality among young 
adults in the US from 1980 to 2002: concealed leveling or mortality 
rates. J Am Coll Cardiol. 2007;50:2128–2132.
5.  CDC National Center for Health Statistics. CDC mortality data, 2008: 
CDC latest release mortality data, 2005. www.cdc.gov/nchs/fastats/
deaths.htm. Accessed 2010 Oct 7.
6.  Sacker A, Head J, Bartley M. Impact of coronary heart disease on 
health functioning in an aging population: are there differences 
according to socioeconomic position? Psychosom Med. 2008;70: 
133–140.
7.  Allender S, Scarborough P, Peto V, et al. European cardiovascular 
disease statistics 2008. European Heart Network, 2008. www.heart-
stats.org/uploads/documents%5Cproof30NOV2007.pdf. Accessed   
2010 Oct 7.
8.  WHO Statistical Information System. Mortality data for ICD 10   codings. 
www.who.int/whosis/database/mort/download/ftp/morticd10.zip. 
Accessed 2010 Oct 7.
  9.  Ridker PM, Danielson E, Fonseca FA, et al; for JUPITER Study 
Group. Rosuvastatin to prevent vascular events in men and 
women with elevated C-reactive protein. N Engl J Med. 2008;359: 
2195–2207.
  10.  Thompson D, Pepys MB, Wood SP. The physiological structure 
of human C-reactive protein and its complex with phosphocholine.   
Structure. 1999;7:169–177.
  11.  Pepys MB, Hirschfield GM. C-reactive protein: a critical update.   
J Clin Invest. 2003;111:1805–1812.
  12.  Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. 
Inflammation, aspirin, and the risk of cardiovascular disease in 
  apparently healthy men. N Engl J Med. 1997;336:973–979.
  13.  Hansson GK, Libby P. The immune response in atherosclerosis:   
a double-edged sword. Nat Rev Immunol. 2006;6:508–519.
  14.  Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion 
molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis 
and incident coronary heart disease cases: the Atherosclerosis Risk in 
Communities (ARIC) study. Circulation. 1997;96:4219–4225.
  15.  Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentra-
tion of interleukin-6 and the risk of future myocardial infarction among 
apparently healthy men. Circulation. 2000;101:1767–1772.
  16.  Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 
1999;340:115–126.
  17.  Libby P, Ridker PM. Inflammation and atherothrombosis: from popula-
tion biology and bench research to clinical practice. J Am Coll Cardiol. 
2006;48:A33–A46.
  18.  Hansson GK. Inflammation, atherosclerosis, and coronary artery 
  disease. N Engl J Med. 2005;352:1685–1695.
  19.  Libby P, Nahrendorf M, Pittet MJ, Swirski FK. Diversity of denizens 
of the atherosclerotic plaque: not all monocytes are created equal. 
Circulation. 2008;117:3168–3170.
  20.  Mach F, Schoenbeck U, Bonnefoy JY, Pober J, Libby P. Activation of 
monocyte/macrophage functions related to acute atheroma complication 
by ligation of CD40. Induction of collagenase, stromelysin, and tissue 
factor. Circulation. 1997;96:396–399.
  21.  Spagnoli LG, Bonanno E, Mauriello A, et al. Multicentric inflammation 
in epicardial coronary arteries of patients dying of acute myocardial 
infarction. J Am Coll Cardiol. 2002;40:1579–1588.
  22.  Abbate A, Bonanno E, Mauriello A, et al. Widespread myocardial 
inflammation and infarct-related artery patency. Circulation. 2004; 
110:46–50.
  23.  Lombardo A, Biasucci LM, Lanza GA, et al. Inflammation as a possible 
link between coronary and carotid plaque instability. Circulation. 2004; 
109:3158–3163.
  24.  Nakajima T, Schulte S, Warrington KJ, et al. T-cell-mediated lysis 
of endothelial cells in acute coronary syndromes. Circulation. 
2002;105:570–575.
  25.  Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular 
risk prediction. J Intern Med. 2002;252:283–294.
  26.  Esposito K, Giugliano D. Diet and inflammation: a link to metabolic 
and cardiovascular diseases. Eur Heart J. 2006;27:15–20.
  27.  Freedman JE, Loscalzo J. Platelet–monocyte aggregates: bridging 
thrombosis and inflammation. Circulation. 2002;105:2130–2132.
  28.  Steinhubl SR. Platelets as mediators of inflammation. Hematol Oncol 
Clin North Am. 2007;21:115–121.
  29.  Nettleton JA, Matijevic N, Follis JL, Folsom AR, Boerwinkle E. Associa-
tions between dietary patterns and flow cytometry-measured biomarkers 
of inflammation and cellular activation in the Atherosclerosis Risk in 
Communities (ARIC) Carotid Artery MRI Study. Atherosclerosis. 
2010;212:260–267.
  30.  Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874.
  31.  Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: 
scientific rationale for the cardiovascular inflammation reduction trial 
(CIRT). J Thromb Haemost. 2009;7(Suppl 1):332–339.
  32.  Brugaletta S, Biasucci LM, Pinnelli M, et al. Novel anti-inflammatory 
effect of statins: reduction of CD4+CD28null T lymphocyte frequency 
in patients with unstable angina. Heart. 2006;92:249–250.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
404
Kones
  33.  Taubes G. Does Inflammation cut to the heart of the matter? Science. 
2002;296:242–245.
  34.  Williams KJ, Tabas I. Atherosclerosis and inflammation. Science. 
2002;297:521–522.
  35.  Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein 
and other markers of inflammation in the prediction of cardiovascular 
disease in women. N Engl J Med. 2000;342:836–843.
  36.  Packard RRS, Libby P. Inflammation in atherosclerosis: from vascu-
lar biology to biomarker discovery and risk prediction. Clin Chem. 
2008;43:24–38.
  37.  Altman R. Risk factors in coronary atherosclerosis ather-inflammation: 
the meeting point. Thrombosis J. 2003;1:4.
  38.  Vorchheimer DA, Fuster V . Inflammatory markers in coronary artery   
disease. Let prevention douse the flames. JAMA. 2001;286:2154–2156.
  39.  Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. 
Nature. 1993;362:801–809.
  40.  Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mono-
nuclear leukocyte adhesion molecule during atherogenesis. Science. 
1991;251:788–791.
  41.  Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker 
of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23: 
168–175.
  42.  Liuzzo G, Biasucci LM, Gallimore JL, et al. The prognostic value of 
C-reactive protein and serum amyloid A protein in severe unstable 
angina. N Engl J Med. 1994;331:417–424.
  43.  Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated level of interleukin-6 in 
unstable angina. Circulation. 1996;94:874–877.
  44.  Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. 
Circulation. 2002;105:1135–1143.
  45.  Wu KK, Aleksic N, Ballantyne Ch M, Ahn Ch, Juneja H, Boerwinkle E. 
Interaction between soluble thrombomodulin and Intercellular Adhesion 
Molecule-1 in predicting risk of coronary heart disease. Circulation. 
2003;107:1729–1732.
  46.  Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. 
Circulation. 2002;106:136–140.
  47.  Kereiakes DJ. The fire that burns within. C-reactive protein. Circulation. 
2003;107:373–374.
  48.  Ridker PM. High-sensitivity C-reactive protein, inflammation, and 
cardiovascular risk: from concept to clinical practice to clinical benefit. 
Am Heart J. 2004;148:S19–S26.
  49.  Dhingra R, Gona P, Nam B-H, et al. C-reactive protein, inflam-
matory conditions, and cardiovascular disease risk. Am J Med. 
2007;120:1054–1062.
  50.  Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed 
adipose tissue: a culprit underlying the metabolic syndrome and ath-
erosclerosis. Atheroscler Thromb Vasc Biol. 2007;27:2276–2283.
  51.  Liu Y, Yu H, Zhang Y, Zhao Y. TLRs are important inflammatory 
factors in atherosclerosis and may be a therapeutic target. Med Hypoth. 
2008;70:314–316.
  52.  Virani SS, Polsani VR, Nambi ZV . Novel markers of inflammatioin in 
atherosclerosis. Curr Atheroscler Rep. 2008;10:164–170.
  53.  Peisajovich A, Marnell L, Mold C, Du Clos TW. C-reactive protein at 
the interface between innate immunity and inflammation. Expert Rev 
Clin Immunol. 2008;4:379–390.
  54.  Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD,   
Kremastinos DT. Inflammatory and non-invasive vascular markers: the 
multimarker approach for risk stratification in coronary artery disease. 
Atherosclerosis. 2008;199;3–11.
  55.  Otake H, Shite J, Shinke T, et al. Relation between plasma adiponectin, 
high sensitivity C-reactive protein, and coronary plaque components 
in patients with acute coronary syndrome. Am J Cardiol. 2008; 
101:1–7.
  56.  Chamberlain J, Francis S, Brookes Z, et al. Interleukin-1 regulates 
multiples atherogenic mechanisms in response to fat feeding. PLoS 
ONE. 2009;4:e5073.
  57.  Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atheroscle-
rosis: transition from theory to practice. Circ J. 2010;74:213–220.
  58.  Ikeda U. Inflammation and coronary artery disease. Curr Vasc 
  Pharmacol. 2003;1:65–70.
  59.  Heinisch RH, Zanetti CR, Comin F, Fernandes JL, Ramires JA, 
  Serrano CV Jr. Serial changes in plasma levels of cytokines in patients 
with coronary artery disease. Vasc Health Risk Manag. 2005;1: 
245–250.
  60.  Ridker PM. Inflammation, high-sensitivity C-reactive protein, and 
vascular protection. Tex Heart Inst J. 2010;37:40–41.
  61.  Curtiss LK. Reversing atherosclerosis? N Eng J Med. 2009;360: 
1144–1146.
  62.  Tillett WS, Francis T Jr. Serological reactions in pneumonia with a non-
protein fraction of pneumococcus. J Exp Med. 1930;52:561–571.
  63.  Norata GD, Marchesi P, Pulakazhi VK, et al. Deficiency of the long 
pentraxin PTX3 promotes vascular inflammation and atherosclerosis. 
Circulation. 2009;120:699–708.
  64.  Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive 
immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91: 
281–291.
  65.  Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between 
autoimmune diseases and atherosclerosis. Autoimmun Rev. 2006;5: 
331–337.
  66.  Sun J, Hartvigsen K, Chou M-Y, et al. Deficiency of antigen-presenting 
cell invariant chain reduces atherosclerosis in mice. Circulation. 2010; 
122:808–820.
  67.  Okemefuna AI, Nan R, Miller A, Gor J, Perkins SJ. Complement factor 
H binds at two independent sites to C-reactive protein in acute phase 
concentrations. J Biol Chem. 2010;285:1053–1065.
  68.  Bodman-Smith KB, Melendez AJ, Campbell I, Harrison PT, Allen JM, 
Raynes JG. C-reactive protein-mediated phagocytosis and phospholi-
pase D signaling through the high-affinity receptor for immunoglobulin 
G (FcγRI). Immunology. 2002;207:252–260.
  69.  Gabay C, Kushner I. Acute-phase proteins and other systemic responses 
to inflammation. N Eng J Med. 1999;340:448–454.
  70.  Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic 
studies of radioiodinated human C-reactive protein in health and disease. 
J Clin Invest. 1993;91:1351–1357.
  71.  Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecu-
lar links between obesity and atheroslcerosis. Am J Physiol Heart Circ 
Physiol. 2005;288:H2031–H2041.
  72.  Brull DJ, Serrano N, Zito F, et al. Human CRP gene polymorphism 
influences CRP levels: implications for the prediction and patho-
genesis of coronary heart disease. Arterioscler Thromb Vasc Biol. 
2003;23:2063–2069.
  73.  Kathiresan S, Larson MG, Vasan RS, et al. Contribution of clinical 
correlates and 13 C-reactive protein gene polymorphisms to inter-
individual variability in serum C-reactive protein level. Circulation. 
2006;113:1415–1423.
  74.  Shah T, Newcombe P, Smeeth L, et al. Ancestry as a determinant 
of mean population C-reactive protein values: implications for 
cardiovascular risk prediction. Circ Cardiovasc Genet. 2010;3: 
436–444.
  75.  Rückerl R, Greven S, Ljungman P, et al; for the Airgene study. Air 
pollution and inflammation (interleukin-6, C-reactive protein, fibrino-
gen) in myocardial infarction survivors. Environ Health Perspect. 
2007;115:1072–1080.
  76.  King DE, Egan BM, Woolson RF, Mainous AG III, Al-Solaiman 
Y, Jesri A. Effect of a high-fiber diet vs a fiber-supplemented 
diet on C-reactive protein level. Arch Intern Med. 2007;167: 
502–506.
  77.  Bo S, Durazzo M, Guidi S, et al. Dietary magnesium and fiber 
intakes and inflammatory and metabolic indicators in middle-aged 
subjects from a population-based cohort. Am J Clinical Nutrition. 
2006;84:1062–1069.
  78.  King DE, Mainous AG III, Egan BM, Woolson RF, Geesey ME. 
Effect of psyllium fiber supplementation on C-reactive protein: 
the trial to reduce inflammatory markers (TRIM). Ann Fam Med. 
2008;6:100–106.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
405
Rosuvastatin, inflammation, CRP, and JUPITER
  79.  Ajani UA, Ford ES, Mokdad AH. Dietary fiber and C-reactive protein: 
findings from national health and nutrition examination survey data.   
J Nutr. 2004;134:1181–1185.
  80.  Zampelas A, Panagiotakos DB, Pitsavos C, et al. Associations between 
coffee consumption and inflammatory markers in healthy persons: the 
ATTICA study. Am J Clin Nutr. 2004;80:862–867.
  81.  Cavicchia PP, Steck SE, Hurley TF, et al. A new dietary inflammatory 
index predicts interval changes in serum high-sensitivity C-reactive 
protein. J Nutr. 2009;139:2365–2372.
  82.  Masters RC, Liese AD, Haffner SM, Wagenknecht LE, Hanley AJ. 
Whole and refined grain intakes are related to inflammatory protein 
concentrations in human plasma. J Nutr. 2010;140:587–594.
  83.  Esmaillzadah A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB,   
Willett WC. Fruit and vegetable intakes, C-reactive protein, and the 
metabolic syndrome. Am J Clin Nutr. 2006:84:1489–2497.
  84.  Micallef MA, Munro IA, Garg ML. An inverse relationship between 
plasma n-3 fatty acids and C-reactive protein in healthy individuals. 
Eur J Clin Nutr. 2009;63:1154–1156.
  85.  Yen ML, Yang CY, Yen BL, et al. Increased high sensitivity C-reactive 
protein and neutrophil count are related to increased standard cardio-
vascular risk factors in healthy Chinese men. Int J Cardiol. 2006;110: 
191–198.
  86.  Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and 
other circulating markers of inflammation in the prediction of coronary 
heart disease. N Engl J Med. 2004;350:1387–1397.
  87.  Faber DR, van der Graaf Y, Westerink J, Visseren FLJ. Increased 
visceral adipose tissue mass is associated with increased C-reactive 
protein in patients with manifest vascular diseases. Atherosclerosis. 
2010;212:274–280.
  88.  Imhof A, Froehlich M, Brenner H, et al. Effect of alcohol consumption 
on systemic markers of inflammation. Lancet. 2001;357:763–767.
  89.  Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma 
concentration of C-reactive protein. Circulation. 2003;107: 443–447.
  90.  Dreon DM, Slavin JL, Phinney SD. Oral contraceptive use and 
increased plasma concentration of C-reactive protein. Life Sci. 2003; 
73:1245–1252.
  91.  Frohlich M, Muhlberger N, Hanke H, et al. Markers of inflammation in 
women on different hormone replacement therapies. Ann Med. 2003; 
35:353–361.
  92.  Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 
2004;279:48487–48490.
  93.  McDade TW, Rutherford JN, Adair L, Kuzawa C. Population differ-
ences in associations between C-reactive protein concentration and 
adiposity: comparison of young adults in the Philippines and the United 
States. Am J Clin Nutr. 2009;89:1237–1245.
  94.  Russell AI, Cunninghame Graham DS, Shepherd C, et al. Polymor-
phism at the C-reactive protein locus influences gene expression and 
predisposes to systemic lupus erythematosus. Hum Mol Genet. 2004; 
13:137–147.
  95.  Jönsen A, Gunnarsson I, Gullstrand B, et al. Association between SLE 
nephritis and polymorphic variants of the CRP and FcγRIIIa genes. 
Rheumatology (Oxford). 2007;46:1417–1421.
  96.  Edberg JC, Wu J, Langefeld CD, et al. Genetic variation in the CRP 
promoter: association with systemic lupus erythematosus (SLE). Hum 
Mol Genet. 2008;17:1147–1455.
  97.  Graf J, Scherzer R, Grunfeld C, Imboden J. Levels of C-reactive 
protein associated with high and very high cardiovascular risk are 
prevalent in patients with rheumatoid arthritis. PLoS ONE. 2009; 
4:e6242.
  98.  Coventry BJ, Ashdown ML, Quinn MA, Markovic SN, Yatomi- 
Clarke SL, Robinson AP. CRP identifies homeostatic immune oscilla-
tions in cancer patients: a potential treatment targeting tool? J Transl 
Med. 2009;7:102.
  99.  Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, 
Tapanainen JS. Metformin reduces serum C-reactive protein levels 
in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 
2003;88:4649–4654.
  100.  Tosi F, Dorizzi R, Castello R, et al. Body fat and insulin resistance 
independently predict increased serum C-reactive protein in hyperan-
drogenic women with polycystic ovary syndrome. Eur J Endocrinol. 
2009;161:737–745.
  101.  Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of 
atorvastatin in patients with polycystic ovary syndrome: a randomized 
double-blind placebo-controlled study. J Clin Endocrinol Metab. 2009; 
94:103–108.
  102.  Hoeger KM. Polycystic ovary syndrome, inflammation and statins: do 
we have the right target? J Clin Endocrinol Metab. 2009;94:35–37.
  103.  De Beer F, Soutar AK, Baltz ML, Trayner IM, Feinstein A,   
Pepys MB. Low density lipoprotein and very low density lipoprotein 
are selectively bound by aggregated C-reactive protein. J Exp Med. 
1982;156:230–242.
  104.  Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive 
protein distribution: its relation to development of atherosclerosis. 
Atherosclerosis. 1999;145:375–379.
  105.  Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of 
C-reactive protein on human endothelial cells. Circulation. 2000;102: 
2165–2168.
  106.  Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the 
arterial intima: role of C-reactive protein receptor-dependent monocyte 
recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000; 
20:2094–2099.
  107.  Devaraj S, Davis B, Simon SI, Jialal I. CRP promotes monocyte-
endothelial cell adhesion via Fcγ receptors in human aortic endothelial 
cells under static and shear flow conditions. Am J Physiol Heart Circ 
Physiol. 2006;291:H1170–H1176.
  108.  Rocker C, Manolov DE, Kuzmenkina EV , et al. Affinity of C-reactive 
protein toward FcgammaRI is strongly enhanced by the gamma-chain. 
Am J Pathol. 2007;170:755–763.
  109.  Schwartz R, Osborne-Lawrence S, Hahner L, et al. C-reactive protein 
downregulates endothelial NO synthase and attenuates reendothelial-
ization in vivo in mice. Circ Res. 2007;100:1452–1459.
  110.  Szmitko PE, Verma S. C-reactive protein and reendothelialization: 
NO involvement. Circ Res. 2007;100:1405–1407.
  111.  Xing D, Hage FG, Chen YF, et al. Exaggerated neointima formation 
in human C-reactive protein transgenic mice is IgG Fc receptor type 1 
(Fc gamma RI)-dependent. Am J Pathol. 2008;172:22–30.
  112.  Salio M, Chimenti S, de Angelis N, et al. Cardioprotective function of 
the long pentraxin PTX3 in acute myocardial infarction. Circulation. 
2008;117:1055–1064.
  113.  Van Vré EA, Bult H, Hoymans VY, van Tendeloo FI, Vrints CJ, 
Bosmans JM. Human C-reactive protein activates monocyte-derived 
dendritic cells and induces dendritic cell-mediated T-cell activation. 
Arterioscler Thromb Vasc Biol. 2008;28:511–518.
  114.  Fujita Y, Kakino A, Nishimichi N, et al. Oxidized LDL receptor 
LOX-1 binds to C-reactive protein and mediates its vascular effects. 
Clin Chem. 2009;55:285–294.
  115.  Filep JG. Platelets affect the structure and function of C-reactive 
protein. Circ Res. 2009;105:109–111.
  116.  Jin C, Lu L, Zhang RY, et al. Association of serum glycated albumin, 
C-reactive protein and ICAM-1 levels with diffuse coronary artery 
disease in patients with type 2 diabetes mellitus. Clin Chim Acta. 
2009;408:45–49.
  117.  Ridker PM. C-reactive protein: eighty years from discovery to emer-
gence as a major risk marker for cardiovascular disease. Clin Chem. 
2009;55:209–215.
  118.  Geluk CA, Post WJ, Hillege HL, et al. C-reactive protein and angio-
graphic characteristics of stable and unstable coronary artery dis-
ease: data from the prospective PREVEND cohort. Atherosclerosis. 
2008;196:372–382.
  119.  Nabata A, Kuroki M, Ueba H, et al. C-reactive protein induces 
endothelial cell apoptosis and matrix metalloproteinase-9 pro-
duction in human mononuclear cells: implications for the desta-
bilization of atherosclerotic plaque. Atherosclerosis. 2008;196: 
129–135.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
406
Kones
  120.  Scirica BM, Cannon CP, Sabatine MS, et al. Concentrations of 
C-reactive protein and B-type natriuretic peptide 30 days after acute 
coronary syndromes independently predict hospitalization for heart 
failure and cardiovascular death. Clin Chem. 2009;55:265–273.
  121.  Scirica BM, Morrow DA, Cannon CP, et al; Thrombolysis in Myocar-
dial Infarction (TIMI) Study Group. Clinical application of C-reactive 
protein across the spectrum of acute coronary syndromes. Clin Chem. 
2007;53:1800–1807.
  122.  Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander 
or proatherogenic culprit? The verdict is still out. Circulation. 
2006;113:2128–2134.
  123.  Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander 
or proatherogenic culprit? C-reactive protein promotes atherothrom-
bosis. Circulation. 2006;113:2135–2150.
  124.  Jialal I, Verma S, Devaraj S. Inhibition of endothelial nitric oxide 
synthase by C-reactive protein: clinical relevance. Clin Chem. 
2009;55:206–208.
  125.  Guan H, Wang P, Hui R, Edin ML, Zeldin DC, Wang DW. Adeno-
associated virus-mediated human C-reactive protein gene delivery 
causes endothelial dysfunction and hypertension in rats. Clin Chem. 
2009;55:274–284.
  126.  Radjesh J, Bisoendial S, Boekholdt M, Vergeer M, Stroes ESG,   
Kastelein JJP. C-reactive protein is a mediator of cardiovascular 
disease. Eur Heart J. 2010;31:2087–2091.
  127.  Sinclair KA, Bogart A, Buchwald D, Henderson JA. The prevalence 
of metabolic syndrome and associated risk factors in Northern Plains 
and Southwest American Indians. Diabetes Care. 2010 Sep 23. [Epub 
ahead of print].
  128.  Kearney MT. Targeting the endothelium to prevent diabetes-related 
atherosclerosis. Diab Vasc Dis Res. 2010;7:177.
  129.  Ford ES, Giles WH, Myers GL, Mannino DM. Population distribu-
tion of high-sensitivity C-reactive protein among US men: findings 
from national health and nutrition examination survey 1999–2000. 
Clin Chem. 2003;49:686–690. http://www.clinchem.org/cgi/content/
full/49/4/686
  130.  Centers for Disease Control and Prevention. NHANES 1999–2000 
public data release file documentation. http://www.cdc.gov/nchs/data/
nhanes/gendoc.pdf. Accessed 2010 Oct 18.
  131.  Rifai N, Ridker PM. Population distributions of C-reactive protein in 
apparently healthy men and women in the United States: implication 
for clinical interpretation. Clin Chem. 2003;49:666–669.
  132.  Woloshin S, Schwartz LM. Distribution of C-reactive protein values 
in the United States. N Eng J Med. 2005;352:1611–1613.
  133.  Kushner I, Rzewnicki W, Samols D. What does minor elevation of 
C-reactive protein signify? Am J Med. 2006;119:166.e17–166.e28.
  134.  Kao PC, Shiesh S-C, Wu T-J. Serum C-reactive protein as a marker 
for wellness assessment. Ann Clin Lab Sci. 2006;36:163–169.
  135.  Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensi-
tive marker of inflammation, predicts future risk of coronary heart 
disease in initially healthy middle-aged men: results from the 
MONICA (Monitoring Trends and Determinants in Cardiovascular 
Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999; 
99:237–242.
  136.  Miller M, Zhan M, Havas S. High attributable risk of elevated 
C-reactive protein level to conventional coronary heart disease risk 
factors: the Third National Health and Nutrition Examination Survey. 
Arch Intern Med. 2005;165:2063–2068.
  137.  Greenfield JR, Samaras K, Jenkins AB, et al. Obesity is an important 
determinant of baseline serum C-reactive protein concentration in 
monozygotic twins, independent of genetic influences. Circulation. 
2004;109:3022–3028.
  138.  Currie CJ, Poole CD, Conway P. Evaluation of the association between 
the first observation and the longitudinal change in C-reactive protein, 
and all-cause mortality. Heart. 2008;94:457–462.
  139.  Marsik C, Kazemi-Shirazi L, Schickbauer T, et al. C-reactive protein 
and all-cause mortality in a large hospital-based cohort. Clin Chem. 
2008;54:343–349.
  140.  Kravitz BA, Corrada MM, Kawas CH. High levels of serum C-reactive 
protein are associated with greater risk of all-cause mortality, but not 
dementia, in the oldest-old: results from the 90+ study. J Am Ger Soc. 
2009;57:641–646.
  141.  Wassel CL, Barrett-Connor E, Laughlin GA. Association of circulat-
ing C-reactive protein and interleukin-6 with longevity into the 80s 
and 90s: The Rancho Bernardo Study. J Clin Endocrinol Metab. 
2010;95:4748–4755.
  142.  Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of 
C-reactive protein and low-density lipoprotein cholesterol   levels in 
the prediction of first cardiovascular events. N Engl J Med. 2002;347: 
1557–1565.
  143.  Diaz JJ, Arguelles J, Malaga I, et al. C-reactive protein is elevated in 
the offspring of parents with essential hypertension. Arch Dis Child. 
2007;92:304–308.
  144.  Mancia G, de Backer G, Dominiczak A, et al. 2007 Guidelines for the 
management of arterial hypertension: The Task Force for the Manage-
ment of Arterial Hypertension of the European Society of Hypertension 
(ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 
2007;28:1462–1536.
  145.  Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure 
reduction, and C-reactive protein: primary report of the Val-MARC 
trial. Hypertension. 2006;48:73–79.
  146.  Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. 
C-reactive protein and the risk of developing hypertension. JAMA. 
2003;290:2945–2951.
  147.  Sathiyapriya V, Nandeesha H, Selvaraj N, Bobby Z, Agrawal A, 
Pavithran P. Association between protein-bound sialic acid and high-
sensitivity C-reactive protein in essential hypertension: a possible 
indication of underlying cardiovascular risk. Angiology. 2009;59: 
721–726.
  148.  Lande MB, Pearson TA, Vermilion RP, Auinger P, Fernandez ID. 
Elevated blood pressure, race/ethnicity, and C-reactive protein levels 
in children and adolescents. Pediatrics. 2008;122:1252–1257.
  149.  Black GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive 
protein, and risk of future cardiovascular events. Circulation. 
2003;108:2993–2999.
  150.  Perticone F, Maio R, Sciacqua A, et al. Enodthelial dysfunction 
and C-reactive protein are risk factors for diabetes in essential 
  hypertension. Diabetes. 2008;57:167–171.
  151.  Vardas PE, Marketou ME. CRP in non-dippers: new perspectives and 
old queries. J Human Hypertension. 2008;22:447–449.
  152.  Veerabhadrappa P, Diaz KM, Feairheller DL, et al. Enhanced 
blood pressure variability in a high cardiovascular risk group of 
African Americans: FIT4 Life Study. J Am Soc Hypertens. 2010;4: 
187–195.
  153.  Iijima R, Byrne RA, Ndrepepa G, et al. Pre-procedural C-reactive 
protein levels and clinical outcomes after percutaneous coronary 
interventions with and without abciximab: pooled analysis of four 
ISAR trials. Heart. 2009;95:107–112.
  154.  Ishii H, Toriyama T, Aoyama T, et al. Prognostic values of C-reactive 
protein levels on clinical outcome after implantation of sirolimus-
eluting stents in patients on hemodialysis. Circ Cardiovasc Interv. 
2009;2:513–518.
  155.  Iliodromitis EK, Kyrzopoulos S, Paraskevaidis IA, et al. Increased 
C reactive protein and cardiac enzyme levels after coronary stent 
implantation. Is there protection by remote ischaemic preconditioning? 
Heart. 2006;92:1821–1826.
  156.  Kangasniemi OP, Biancari F, Luukkonen J, et al. Preopera-
tive C-reactive protein is predictive of long-term outcome after 
coronary artery bypass surgery. Eur J Cardiothorac Surg. 2006;29: 
983–985.
  157.  Wypasek E, Undas A, Sniezek-Maciejewska M, et al. The increased 
plasma C-reactive protein and interleukin-6 levels in patients under-
going coronary artery bypass grafting surgery are associated with 
the interleukin-6-174G . C gene polymorphism. Ann Clin Biochem. 
2010;47:343–349.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
407
Rosuvastatin, inflammation, CRP, and JUPITER
  158.  Lo B, Fijnheer R, Nierich AP, Bruins P, Kalkman CJ. C-reactive 
protein is a risk indicator for atrial fibrillation after myocardial revas-
cularization. Ann Thorac Surg. 2005;79:1530–1535.
  159.  Kardys I, Knetsch AM, Bleumink GS, et al. C-reactive protein 
and risk of heart failure. The Rotterdam Study. Am Heart J. 
2006;152:514–520.
  160.  Williams ES, Shah SJ, Ali S, Na BY, Schiller NB, Whooley MA. 
C-reactive protein, diastolic dysfunction, and risk of heart failure in 
patients with coronary disease: Heart and Soul Study. Eur J Heart 
Fail. 2008;10:63–69.
  161.  Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358: 
2148–2159.
  162.  Bozkurt B, Mann DL, Deswal A. Biomarkers of inflammation in heart 
failure. Heart Fail Rev. 2010;15:331–341.
  163.  Araujo JP, Lourenco P, Azevedo A, et al. Prognostic value of high-
sensitivity C-reactive protein in heart failure: a systematic review.   
J Cardiac Fail. 2009;15:256–266.
  164.  Collinson PO. Concentrations of C-reactive protein and B-type natri-
uretic peptide 30 days after acute coronary syndromes independently 
predict hospitalization for heart failure and cardiovascular death: just 
another brick in the wall? Clin Chem. 2009:55:203–205.
  165.  Lamblin N, Mouquet F, Hennache B, et al. High-sensitivity C-reactive 
protein: potential adjunct for risk stratification in patients with stable 
congestive heart failure. Eur Heart J. 2005;26:2245–2250.
  166.  Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart 
failure: prognostic value and the effect of valsartan. Circulation. 
2005;112:1428–1434.
  167.  Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory mark-
ers and risk of heart failure in elderly subjects without prior 
myocardial infarction: the Framingham Heart Study. Circulation. 
2003;107:1486–1491.
  168.  Conen D, Rexrode KM, Creager MA, Ridker PM, Pradhan AD. 
Metabolic syndrome, inflammation, and risk of symptomatic periph-
eral artery disease in women: a prospective study. Circulation. 
2009;120:1041–1047.
  169.  Pande RL, Perlstein TS, Beckman JA, Creager MA. Association of 
insulin resistance and inflammation with peripheral arterial disease: 
the National Health and Nutrition Examination Survey, 1999 to 2004. 
Circulation. 2008;118(1):33–41.
  170.  Schlager O, Exner M, Mlekusch W, et al. C-reactive protein predicts 
future cardiovascular events in patients with carotid stenosis. Stroke. 
2007;38:1263–1268.
  171.  Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, 
homocysteine, and plasma lipid levels as predictors of sudden cardiac 
death. Circulation. 2002;4(105):2595–2599.
  172.  Spooner PM, Zipes DP. Sudden death predictors: an inflammatory 
association. Circulation. 2002;105:2574–2576.
  173.  Beri A, Contractor T, Khasnis A, Thakur R. Statins and the reduction 
of sudden cardiac death: antiarrhythmic or anti-ischemic effect? Am 
J Cardiovasc Drugs. 2010;10:155–164.
  174.  Corbalán R, Braun S, Pereira J, Navarrete C, Gonzalez I. C-  reactive 
protein and atrial fibrillation: evidence for the presence of inflamma-
tion in the perpetuation of the arrhythmia. Int J Cardiol. 2006;108: 
326–331.
  175.  Conen D, Ridker PM, Everett BM, et al. A multimarker approach to 
assess the influence of inflammation on the incidence of atrial fibril-
lation in women. Eur Heart J. 2010;31:1730–1736.
  176.  Marott SCW, Nordestgaard BG, Zacho J, et al. Does elevated 
C-  reactive protein increase atrial fibrillation risk? A mendelian 
randomization of 47,000 individuals from the general population.   
J Am Coll Cardiol. 2010;56:789–795.
  177.  Blangy H, Sadoul N, Dousset B, et al. Serum BNP, hs-C-reactive 
protein, procollagen to assess the risk of ventricular tachycardia in ICD 
recipients after myocardial infarction. Europace. 2007;9:724–729.
  178.  Jeevanantham V , Singh N, Izuora K, D’souza JP, His DH. Correlation 
of high sensitivity C-reactive protein and calcific aortic valve disease. 
Mayo Clin Proc. 2007;82:171–174.
  179. Jones P, Davidson M, Stein E, et al. Comparison of the efficacy 
and safety of rosuvastatin versus atorvastatin, simvastatin, and 
pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003; 
92:152–160.
  180.  Ay C, Tengler T, Vormittag R, et al. Venous thromboembolism a 
manifestation of the metabolic syndrome. Haematologica. 2007;92: 
374–380.
  181.  Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein a new 
predictor of adverse outcome in pulmonary arterial hypertension.   
J Am Coll Cardiol. 2009;53:1211–1218.
  182.  Soinio M, Marniemi J, Laakso M, et al. High-sensitivity C-reactive pro-
tein and coronary heart disease mortality in patients with type 2   diabetes: 
a 7-year follow-up study. Diabetes Care. 2006;29:329–333.
  183.  Marcovecchio ML, Giannini C, Widmer B, et al. C-reactive protein in 
relation to the development of microalbuminuria in type 1 diabetes. 
Diabetes Care. 2008;31:974–976.
  184.  Dehghan A, Kardys I, de Maat MPM, et al. Genetic variation, 
C-reactive protein levels, and incidence of diabetes. Diabetes. 2007; 
56:872–878.
  185.  Kahn SE, Zinman B, Haffner SM, et al. Obesity is a major determi-
nant of the association of C-reactive protein levels and the metabolic 
syndrome in type 2 diabetes. Diabetes. 2006;55:2357–2364.
  186.  Goldberg RB. Cytokine and cytokine-like inflammation markers, 
endothelial dysfunction, and imbalanced coagulation in develop-
ment of diabetes and its complications. J Clin Endocrinol Metab. 
2009;94:3171–3182.
  187.  Ridker PM, Pare G, Parker A, et al. Loci related to metabolic-syndrome 
pathways including LEPR, HNF1A, IL6R, and GCKR associate with 
plasma C-reactive protein: the Women’s Genome Health Study. Am 
J Hum Genet. 2008;82:1185–1192.
  188.  Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the 
metabolic syndrome, and risk of incident cardiovascular events: 
an 8-year follow-up of 14,719 initially healthy American women.   
Circulation. 2003;107;391–397.
  189.  Moreno-Navarrete JM, Martinez-Barricarte R, Catalan V, et al. 
Complement factor H is expressed in adipose tissue in association 
with insulin resistance. Diabetes. 2010;59:200–209.
  190.  Jialal I. The role of the laboratory in the diagnosis of the metabolic 
syndrome. Am J Clin Pathol. 2009;132(2):161–162.
  191.  Steinberger J, Daniels SR, Eckel RH, et al; American Heart Association 
Atherosclerosis, Hypertension, and Obesity in the Young Committee 
of the Council on Cardiovascular Disease in the Young; Council on 
Cardiovascular Nursing; and Council on Nutrition, Physical Activity, 
and Metabolism. Progress and challenges in metabolic syndrome in 
children and adolescents: a scientific statement from the American 
Heart Association Atherosclerosis, Hypertension, and Obesity in the 
Young Committee of the Council on Cardiovascular Disease in the 
Young; Council on Cardiovascular Nursing; and Council on Nutrition, 
Physical Activity, and Metabolism. Circulation. 2009;119:628–647.
  192.  Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. 
Endocr Rev. 2008;29:777–822.
  193.  Suzuki T, Katz R, Jenny NS, et al. Metabolic syndrome, inflammation, 
and incident heart failure in the elderly: the Cardiovascular Health 
Study. Circ Heart Fail. 2008;1:242–248.
  194.  You T, Nicklas BJ, Ding J, et al. The metabolic syndrome is associ-
ated with circulating adipokines in older adults across a wide range 
of adiposity. J Gerontol A Biol Sci Med Sci. 2008;63:414–419.
  195.  Dai DF, Lin JW, Kao JH, et al. The effects of metabolic syndrome 
versus infectious burden on inflammation, severity of coronary athero-
sclerosis, and major adverse cardiovascular events. J Clin Endocrinol 
Metab. 2007;92:2532–2537.
  196.  Ye X, Yu Z, Li H, Franco OH, Liu Y, Lin X. Distributions of C-reactive 
protein and its association with metabolic syndrome in middle-aged 
and older Chinese people. J Am Coll Cardiol. 2007;49:1798–1805.
  197.  Pitsavos C, Panagiotakos DB, Tzima N, et al. Diet, exercise, and 
C-reactive protein levels in people with abdominal obesity: the 
ATTICA epidemiological study. Angiology. 2007;58:225–233.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
408
Kones
  198.  Devaraj S, Valleggi D, Siegel D, Jialal I. Role of C-reactive protein in 
contributing to increased cardiovascular risk in metabolic syndrome. 
Curr Atheroscler Rep. 2010;12:110–118.
  199.  Wang A, Nakayama T. Inflammation, a link between obesity and 
cardiovascular disease. Mediators Inflamm. 2010;2010:535918.
  200.  Alyan O, Metin F, Kacmaz F, et al. High levels of high sensitivity 
C-reactive protein predict the progression of chronic rheumatic mitral 
stenosis. J Thromb Thrombolysis. 2009;28:63–69.
  201.  Lee HM, Le TV, Lopez VA, Wong ND. Association of C-reactive 
protein with reduced forced vital capacity in a nonsmoking US 
population with metabolic syndrome and diabetes. Diabetes 
Care. 2008;31:2000–2002.
  202.  Magnussen H, Watz H. Systemic inflammation in chronic obstructive 
pulmonary disease and asthma: relation with comorbidities. Proc Am 
Thorac Soc. 2009;6:648–651.
  203.  Eickhoff P, Valipour A, Kiss D, et al. Determinants of systemic vas-
cular function in patients with stable chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med. 2008;178:1211–1218.
  204.  Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syn-
drome: mechanistic links to chronic kidney disease. J Am Soc Nephrol. 
2007;2:550–562.
  205. Chen HY, Chiu YL, Hsu SP, et al. Elevated C-reactive protein level in 
hemodialysis patients with moderate/severe uremic pruritus: a poten-
tial mediator of high overall mortality. QJM. 2010;103: 837–846.
  206.  Lahrach H, Ghalim N, Taki H, et al. Serum paraoxonase activity, 
high-sensitivity C-reactive protein, and lipoprotein disturbances in 
end-stage renal disease patients on long-term hemodialysis. J Clin 
Lipidol. 2008;2:43–50.
  207.  Lui MM, Lam JC, Mak HK-F, et al. C-reactive protein is associated 
with obstructive sleep apnea independent of visceral obesity. Chest. 
2009;135:950–956.
  208.  Schiza SE, Mermigkis C, Panagiotis, et al. C-reactive protein evolution 
in obstructive sleep apnoea patients under CPAP therapy. Eur J Clin 
Invest. 2010;40:968–975.
  209.  Zeka A, Sullivan JR, Vokonas PS, Sparrow D, Schwartz J. Inflamma-
tory markers and particulate air pollution: characterizing the pathway 
to disease. Int J Epidemiol. 2006;35:1347–1354.
  210.  Dixon JB, Hayden MJ, Lambert GW, et al. Raised CRP Levels in 
obese patients: symptoms of depression have an independent positive 
association. Obesity. 2008;16:2010–2015.
  211.  Hak AE, Stehouwer CD, Bots ML, et al. Associations of C-reactive 
protein with measures of obesity, insulin resistance, and subclinical 
atherosclerosis in healthy, middle-aged women. Arterioscler Thromb 
Vasc Biol. 1999;19:1986–1991.
  212.  McLaughlin T, Abbasi F, Lamendola C, et al. Differentiation between 
obesity and insulin resistance in the association with C-reactive protein. 
Circulation. 2002;106:2908–2912.
  213.  Wee CC, Mukamal KJ, Huang A, Davis RB, McCarthy EP, 
Mittleman MA. Obesity and C-reactive protein levels among white, 
black, and hispanic US adults. Obesity. 2008;16:875–880.
  214.  Skinner AC, Steiner MJ, Henderson FW, Perrin EM. Mul-
tiple markers of inflammation and weight status: cross-sec-
tional analyses throughout childhood. Pediatrics. 2010;125: 
e801–e809.
  215.  Puglisi MJ, Fernandez ML. Modulation of C-reactive protein, tumor 
necrosis factor α, and adiponectin by diet, exercise, and weight loss. 
J Nutr. 2008;138:2293–2296.
  216.  Sacheck J. Pediatric obesity: an inflammatory condition? JPEN   
J Parenter Enteral Nutr. 2008;32:633–637.
  217.  Rankin JW, Turpyn AD. Low carbohydrate, high fat diet increases 
C-reactive protein during weight loss. J Am Coll Nutr. 2007;26: 
163–169.
  218.  Selvin E, Paynter NP, Erlinger TP. The effect of weight loss on 
C-reactive protein: a systematic review. Arch Intern Med. 2007;167: 
31–39.
  219.  Pope CA III. Particulate air pollution, C-reactive protein, and cardiac 
risk. Eur Heart J. 2001;22:1149–1150.
  220.  Nicklas BJ, You T, Pahor M. Behavioural treatments for chronic 
systemic inflammation: effects of dietary weight loss and exercise 
training. CMAJ. 2005;172:1199–1209.
  221.  Gentile M, Panico S, Rubba F, et al. Obesity, overweight, and 
weight gain over adult life are main determinants of elevated hs-
CRP in a cohort of Mediterranean women. Eur J Clin Nutr. 2010;64: 
873–878.
  222.  Hamer M, Steptoe A. Prospective study of physical fitness, adiposity, 
and inflammatory markers in healthy middle-aged men and women. 
Am J Clin Nutr. 2009;89:85–89.
  223.  Welsh P, Polisecki E, Robertson M, et al. Unraveling the directional 
link between adiposity and inflammation: a bidirectional   Mendelian 
randomization approach. J Clin Endocrinol Metab. 2010;95: 
93–99.
  224.  Hubel CA, Powers RW, Snaedal S, et al. C-reactive protein is 
elevated 30 years after eclamptic pregnancy. Hypertension. 2008;51: 
1499–1505.
  225.  Lau B, Sharrett SR, Kingsley LA, et al. C-reactive protein is a marker 
for human immunodeficiency virus disease progression. Arch Intern 
Med. 2006;166:64–70.
  226.  Surtees PG, Wainwright NWJ, Boekholdt SM, Luben RN, 
Wareham NJ, Khaw KT. Major depression, C-reactive protein, and 
incident ischemic heart disease in healthy men and women. Psychosom 
Med. 2008;70:850–855.
  227.  Ridker PM. High-sensitivity C-reactive protein: potential adjunct for 
global risk assessment in the primary prevention of cardiovascular 
disease. Circulation. 2001;103:1813–1818.
  228.  Pankow JS, Folsom AR, Cushman M, et al. Familial and genetic 
determinants of systemic markers of inflammation: the NHLBI family 
heart study. Atherosclerosis. 2001;154:681–689.
  229.  Lee CC, You NC, Song Y, et al. Relation of genetic variation in the gene 
coding for C-reactive protein with its plasma protein concentrations: 
findings from the Women’s Health Initiative Observational Cohort. 
Clin Chem. 2009;55(2):351–360.
  230.  Kelley-Hedgepeth A, Lloyd-Jones DM, Colvin A, et al. Ethnic dif-
ferences in C-reactive protein concentrations. Clin Chem. 2008;54: 
1027–1037.
  231.  Smith GD, Ebrahim S. Mendelian randomization: can genetic epide-
miology contribute to understanding environmental determinants of 
disease? Int J Epidemiol. 2003;32:1–22.
  232.  Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H,   
Nordestgaard BG. Genetically elevated C-reactive protein and isch-
emic vascular disease. N Engl J Med. 2008;359:1897–1908.
  233.  Smith DG. Capitalizing on Mendelian randomization to assess the 
effects of treatments. J R Soc Med. 2007;100:432–435.
  234.  Sheehan NA, Didelez V , Burton PR, Tobin MD. Mendelian randomisa-
tion and causal inference in observational epidemiology. PLoS Med. 
2008;5:e177.
  235.  Elliott P, Chambers JC, Zhang W, et al. Genetic loci associated with 
C-reactive protein levels and risk of coronary heart disease. JAMA. 
2009;302:37–48.
  236.  Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, 
and limitations. Int J Epidemiol. 2004;33:30–42.
  237.  Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, 
Lowe G, et al. C-reactive protein concentration and risk of coronary 
heart disease, stroke, and mortality: an individual participant meta-
analysis. Lancet. 2010;375:132–140.
  238.  Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels 
and subsequent risk of coronary heart disease: two new prospective 
studies and a systematic review. PLoS Med. 2008;5:e78.
  239.  Clarke R, Emberson JR, Breeze E, et al. Biomarkers of inflammation 
predict both vascular and non-vascular mortality in older men. Eur 
Heart. 2008;29:800–809.
  240.  Heikkila K, Harris R, Lowe G, et al. Associations of circulating 
C-reactive protein and interleukin-6 with cancer risk: findings from 
two prospective cohorts and a meta-analysis. Cancer Causes Control. 
2009;20:15–26.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
409
Rosuvastatin, inflammation, CRP, and JUPITER
  241.  Habersberger J, Eisenhardt S, Peter K. C-reactive protein measurement 
and cardiovascular disease. Original Text. Lancet. 2010;9720: 
1078.
  242.  Ji SR, Wu Y, Zhu L, et al. Cell membranes and liposomes dissociate 
C-reactive protein (CRP) to form a new, biologically active structural 
intermediate: mCRP(m). FASEB J. 2007;21:284–294.
  243.  Molins B, Peña E, Vilahur G, Mendieta C, Slevin M, Badimon L. 
C-reactive protein isoforms differ in their effects on thrombus growth. 
Arterioscler Thromb Vasc Biol. 2008;28:2239–2246.
  244.  Eisenhardt SU, Habersberger J, Murphy A, et al. Dissociation of 
pentameric to monomeric C-reactive protein on activated platelets 
localizes inflammation to atherosclerotic plaques. Circ Res. 2009; 
105:128–137.
  245.  Ji SR, Ma L, Bai CJ, et al. Monomeric C-reactive protein activates 
endothelial cells via interaction with lipid raft microdomains. FASEB J. 
2009;23:1806–1816.
  246.  Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive 
protein for the targeting of statin therapy in the primary prevention of 
acute coronary events. N Engl J Med. 2001;344:1959–1965.
  247. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coro-
nary atherosclerosis in asymptomatic teenagers and young adults: 
evidence from intravascular ultrasound. Circulation. 2001;103: 
2705–2710.
  248.  Ridker PM, Cannon CP, Morrow D, et al; Atorvastatin Evaluation and 
Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE 
IT – TIMI 22) Investigators. C-reactive protein levels and outcomes 
after statin therapy. N Engl J Med. 2005;352:20–28.
  249.  De Beer FC, Hind CR, Fox KM, et al. Measurement of serum 
C-  reactive protein concentration in myocardial ischaemia and infarc-
tion. Br Heart J. 1982;47:239–243.
  250.  Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive 
protein and risk of coronary events in stable and unstable angina. 
European Concerted Action on Thrombosis and Disabilities Angina 
Pectoris Study Group. Lancet. 1997;349:462–466.
  251.  Niccoli G, Biasucci LM, Biscione C, et al. Independent prognostic 
value of C-reactive protein and coronary artery disease extent in 
patients affected by unstable angina. Atherosclerosis. 2008;196: 
779–785.
  252.  Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of 
C-reactive protein and risk of developing peripheral vascular disease. 
Circulation. 1998;97:425–428.
  253.  Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL 
cholesterol, C-reactive protein, and coronary artery disease. N Engl J 
Med. 2005;352:29–38.
  254.  Hemingway H, Philipson P, Chen R, Fitzpatrick NK, Damant J, 
et al. Evaluating the quality of research into a single prognostic 
biomarker: a systematic review and meta-analysis of 83 studies of 
C-reactive protein in stable coronary artery disease. PLoS Med. 2010;7: 
e1000286.
  255.  Boekholdt SM, Hack CE, Sandhu MS, et al. C-reactive protein levels 
and coronary artery disease incidence and mortality in apparently 
healthy men and women: the EPIC-Norfolk prospective population 
study 1993–2003. Atherosclerosis. 2006;187:415–422.
  256.  Cook NR, Buring JE, Ridker PM. The effect of including C-reactive 
protein in cardiovascular risk prediction models for women. Ann Intern 
Med. 2006;145:21–29.
  257.  Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovas-
cular Society/Canadian guidelines for the diagnosis and treatment 
of dyslipidemia and prevention of cardiovascular disease in the 
adult – 2009 recommendations. Can J Cardiol. 2009;25:567–579.
  258.  Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive 
protein and the calculated Framingham Coronary Heart Disease Risk 
Score. Circulation. 2003;108:161–165.
  259.  Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL 
cholesterol, apolipoproteins A-I and B100, standard lipid measures, 
lipid ratios, and CRP as risk factors for cardiovascular disease in 
women. JAMA. 2005;294:326–333.
  260.  Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP 
measurement for the prediction of coronary heart disease events: new 
data and systematic review of 31 prospective cohorts. Int J Epidemiol. 
2009; 38:217–231.
  261.  Wald DS, Kasturiratne A, Bestwick JP. The value of C-reactive protein 
in screening for future coronary heart disease events. J Med Screen. 
2009;16:212–214.
  262.  Lakoski SG, Greenland P, Wong ND, Schreiner PJ, et al. Coronary 
artery calcium scores and risk for cardiovascular events in women 
classified as “low risk” based on Framingham risk score: the Multi-
Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2007; 
167:2437–2442.
  263.  Ridker PM, Buring JE, Rifai N, Cook NR. Development and valida-
tion of improved algorithms for the assessment of global cardiovas-
cular risk in women: the Reynolds Risk Score. JAMA. 2007;297: 
611–619.
  264.  Wilson PW, Pencina M, Jacques P, Selhub J, D’Agostino Sr R, 
O’Donnell CJ. C-reactive protein and reclassification of cardiovascular 
risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 
2008;1:92–97.
  265.  Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive 
protein and parental history improve global cardiovascular risk pre-
diction: the Reynolds Risk Score for Men. Circulation. 2008;118: 
2243–2251.
  266.  Cook NR. The case for C-reactive protein as a risk marker for coronary 
heart disease. Ann Intern Med. 2010;152:406.
  267.  Cook NR, Ridker PM. Advances in measuring the effect of individual 
predictors of cardiovascular risk: the role of reclassification measures. 
Ann Intern Med. 2009;50:795–802.
  268.  Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline 
high-sensitivity C-reactive protein level to cardiovascular outcomes 
with rosuvastatin in the Justification for Use of statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol. 
2010;106:204–209.
 269.  Slejko JF, Page RL II, Sullivan PW. Implications of Jupiter   prevention 
in adults with elevated C-reactive protein: statin therapy is cost- 
effective for vascular event. J Am Coll Cardiol. 2010;55: 
A131.E1229.
  270.  Rao AD, Milbrandt EB. To JUPITER and beyond: statins, inflamma-
tion, and primary prevention. Critical Care. 2010;14:310.
  271.  MacDonald GP. Cost-effectiveness of rosuvastatin for primary preven-
tion of cardiovascular events according to Framingham Risk Score 
in patients with elevated C-reactive protein. J Am Osteopath Assoc. 
2010;110:427–436.
  272.  Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen,   
C-reactive protein, albumin, or leukocyte count with coronary heart 
disease: meta-analyses of prospective studies. JAMA. 1998;279:   
1477–1482.
  273.  Danesh J, Whincup P, Walker M, et al. Low grade inflammation and 
coronary heart disease: prospective study and updated meta-analyses. 
BMJ. 2000;321:199–204.
  274.  Nambi V, Ballantyne CM. Utility of statin therapy using high-
  sensitivity C-reactive protein as an indicator of coronary heart disease 
risk. Curr Atheroscler Rep. 2005;7:22–28.
  275.  Ridker PM. High-sensitivity C-reactive protein and cardiovascular 
risk: rationale for screening and primary prevention. Am J Cardiol. 
2003;92:17K–22K.
  276.  Roche VF. Antihyperlipidemic statins: a self-contained, clinically 
relevant medicinal chemistry lesson. Am J Pharm Educ. 2005;69: 
546–560.
  277.  Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition 
of HMG-CoA reductase. Science. 2001;292:1160–1164.
  278.  Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the 
pharmacology and clinical effects of HMG-CoA reductase inhibitors. 
Trends Pharmacol Sci. 1998;19:26–37.
  279.  McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler 
Suppl. 2003;4:9–14.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
410
Kones
  280.  Kapur NK. Rosuvastatin: a highly potent statin for the prevention and 
management of coronary artery disease. Expert Rev Cardiovasc Ther. 
2007;5:161–175.
  281.  Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in 
statin drug interactions. Pharmacotherapy. 2006;26:1601–1607.
  282.  Kostapanos MS, Haralampos J, Elisaf MS. Rosuvastatin-associated 
adverse effects and drug-drug interactions in the clinical setting of 
dyslipidemia. Am J Cardiovasc Drugs. 2010;10:11–28.
  283.  Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment 
  Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-
lowering   treatment: prospective meta-analysis of data from 
90,056 participants in 14 randomized trials of statins. Lancet. 
2005;366:1267–1278.
  284.  McKenney JM. Pharmacologic options for aggressive low-density 
lipoprotein cholesterol lowering: benefits versus risks. Am J Cardiol. 
2005;96:60E–66E.
  285.  The  Galaxy  Program.  http://www.galaxyprogramme.org/
about-galaxy/?itemId=2592383. Accessed 2010 Oct 18.
  286.  Crouse JR III, Raichlen JS, Riley WA, et al; METEOR study group. 
Effect of rosuvastatin on progression of carotid intima-media thickness 
in low-risk individuals with subclinical atherosclerosis. JAMA. 2007; 
297:1344–1353.
  287.  Crouse JR III, Bots ML, Evans GW, et al. Does baseline carotid 
intima-media thickness modify the effect of rosuvastatin when 
compared with placebo on carotid intima-media thickness pro-
gression? The METEOR study. Eur J Cardiovasc Prev Rehabil. 
2010;17:223–229.
  288.  Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older 
patients with systolic heart failure. N Engl J Med. 2007;357: 
2248–2261.
  289.  McMurray JJV , Kjekshus J, Gullestad L, et al; CORONA Study Group. 
Effects of statin therapy according to plasma high-sensitivity C-reactive 
protein concentration in the Controlled Rosuvastatin Multinational trial 
in Heart Failure (CORONA). A retrospective analysis. Circulation. 
2009;120:2188–2196.
  290.  Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, et al. 
Effect of rosuvastatin in patients with chronic heart failure (the 
GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. 
Lancet. 2008;372:1231–1239.
  291.  Van der Harst P, de Boer RA. Statins in the treatment of heart failure. 
Circ Heart Fail. 2010;3:462–464.
  292.  Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and 
cardiovascular events in patients undergoing hemodialysis. N Eng J 
Med. 2009;373:1175–1182.
  293.  Narla V , Blaha MJ, Blumenthal RS, Michos ED. The JUPITER and 
AURORA clinical trials for rosuvastatin in special primary prevention 
populations: perspectives, outcomes, and consequences. Vasc Health 
Risk Manag. 2009;5:1033–1042.
  294.  Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity 
statin therapy on regression of coronary atherosclerosis: the   
ASTEROID trial. JAMA. 2006;295:1556–1565.
  295.  Ballantyne CM, Raichlen JS, Nicholls S, et al; ASTEROID 
Investigators. Effect of rosuvastatin therapy on coronary artery 
stenoses assessed by quantitative coronary angiography: a study 
to evaluate the effect of rosuvastatin on intravascular ultrasound-
derived coronary atheroma burden. Circulation. 2008;117: 
2458–2466.
  296.  Mack WJ, Xiang M, Selzer RH, Hodis HN. Serial quantitative 
coronary angiography and coronary events. Am Heart J. 2000;139: 
993–999.
  297.  Buchwald H, Matts JP, Fitch LL, et al; Program on the Surgical Con-
trol of the Hyperlipidemias (POSCH) Group. Changes in sequential 
coronary arteriograms and subsequent coronary events. JAMA. 
1992;268:1429–1433.
  298.  Fonseca FAH, Izar MCO. Primary prevention of vascular events in 
patients with high levels of C-reactive protein: the JUPITER Study. 
Expert Rev Cardiovasc Ther. 2009;7:1041–1056.
  299.  Libby P, Ridker PM. Novel inflammatory markers of coronary risk: 
theory versus practice. Circulation. 1999;100:1148–1150.
  300.  Lemieux I, Pascot A, Prud’homme D, Almeras N, et al. Elevated 
C-reactive protein: another component of the atherothrombotic pro-
file of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001;21: 
961–967.
  301.  Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and 
the risk of coronary events after myocardial infarction in patients with 
average cholesterol levels. Cholesterol and Recurrent Events (CARE) 
Investigators. Circulation. 1998;98:839–844.
  302.  Ridker PM; JUPITER Study Group. Rosuvastatin in the primary 
prevention of cardiovascular disease among patients with low levels 
of low-density lipoprotein cholesterol and elevated high-sensitivity 
C-reactive protein: rationale and design of the JUPITER trial. 
  Circulation. 2003;108:2292–2297.
  303.  Ridker PM, Fonseca FAH, Genest J, et al; JUPITER Trial Study 
Group. Baseline characteristics of participants in the JUPITER Trial, 
a randomized placebo-controlled primary prevention trial of statin 
therapy among individuals with low low-density lipoprotein choles-
terol and elevated high-sensitivity C-reactive protein. Am J Cardiol. 
2007;100:1659–1664.
  304.  De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. 
Mediterranean diet, traditional risk factors, and the rate of cardiovas-
cular complications after myocardial infarction – final report of the 
Lyon Diet Heart Study. Circulation. 1999;99:779–785.
  305.  Rembold CM. To statin or to non-statin in coronary disease –   considering 
absolute risk is the answer. Atherosclerosis. 2007;195:1–6.
  306.  Everett BM, Ridker PM. Using inflammatory biomarkers to guide 
lipid therapy. Curr Cardiovasc Risk Reports. 2008;2:29–34.
  307.  Kritek P, Campion EW. JUPITER Clinical Directions – polling results. 
N Eng J Med. 2009;360:e14.
  308.  Spatz ES, Canavan ME, Desai MM. From here to JUPITER. Identi-
fying new patients for statin therapy using data from the 1999–2004 
National Health and Nutrition Examination Survey. Circ Qual 
  Outcomes. 2009;2:41–48.
  309.  Michos ED, Blumenthal RS. Prevalence of the JUPITER   (Justification 
for the Use of Statins in Primary Prevention: an Intervention Trial 
Evaluating Rosuvastatin) Study. J Am Coll Cardiol. 2009;53: 
931–935.
  310.  Ridker PM. The JUPITER trial. Results, controversies, and implications 
for prevention. Circ Cardiovasc Qual Outcomes. 2009;2:279–285.
  311.  Ridker PM, MacFadyen JG, Fonseca FAH, et al; JUPITER Study 
Group. Number needed to treat with rosuvastatin to prevent first 
cardiovascular events and death among men and women with low 
low-density lipoprotein cholesterol and elevated high-sensitivity 
C-reactive protein. Justification for the Use of statins in Prevention: 
an Intervention Trial Evaluation Rosuvastatin (JUPITER). Circ Car-
diovasc Qual Outcomes. 2009;2:616–623.
  312.  Yang EY, Nambi V , Tang Z, et al. Clinical implications of JUPITER 
(Justification for the Use of statins in Prevention: an Intervention Trial 
Evaluating Rosuvastatin) in a US population: insights from the ARIC 
(Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 
2009;54:2388–2395.
  313.  Vaccarino V , Bremmer JD, Kelley ME. JUPITER. A few words of 
caution. Circ Cardiovasc Qual Outcomes. 2009;2:286–288.
  314.  Kones R. Recent advances in the management of chronic stable 
angina. II. Anti-ischemic therapy, options for refractory angina, risk 
factor reduction, and revascularization. Vasc Health Risk Manag. 
2010;6:749–774.
  315.  Eyre H, Kahn R, Robertson RM. Preventing cancer, cardiovascular 
disease, and diabetes: a common agenda for the American Cancer 
Society, the American Diabetes Association, and the American Heart 
Association. Diabetes Care. 2004;27:1812–1824.
  316.  Levi J, Segal LM, Juliano C. Prevention for a healthier America: 
investments in disease prevention yield significant savings, stronger 
communities: Trust for America’s Health. Issue Report 2008 Jul. http://
healthyamericans.org/reports/prevention08/. Accessed 2010 Sep 1.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
411
Rosuvastatin, inflammation, CRP, and JUPITER
  317.  Heart Protection Study Collaborative Group. Statin cost-effectiveness 
in the United States for people at different vascular risk levels. Circ 
Cardiovasc Qual Outcomes. 2009;2:65–72.
  318.  Accad M, Fred HL. Is JUPITER also a God of primary prevention? 
Tex Heart Inst J. 2010;37:6–7.
  319.  Kappagoda CT, Amsterdam EA. Another look at the results of the 
JUPITER trial. Am J Cardiol. 2009;104:1603–1605.
  320.  Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive 
protein and LDL cholesterol and cardiovascular event rates after 
initiation of rosuvastatin: a prospective study of the JUPITER trial. 
Lancet. 2009;373:1175–1182.
  321.  Despres JP. Bringing JUPITER down to Earth. Lancet. 2009;373: 
1147–1148.
  322.  Kostapanos MS, Milionis HJ, Elisaf MS. An overview of the 
extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther. 
2008;13:157–174.
  323.  Kendrick M. Should women be offered cholesterol lowering drugs to 
prevent cardiovascular disease? No. BMJ. 2007;334:983.
  324.  Eisenberg T, Wells M. Statins and adverse cardiovascular events 
in moderate-risk females: a statistical and legal analysis with 
implications for FDA preemption claims. J Empir Leg Stud. 
2008;5:507–550.
  325.  Rosenberg H, Allard D. Women and statin use: a women’s health 
advocacy perspective. Scand Cardiovasc J. 2008;42:268–273.
  326.  Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. 
Statins for the primary prevention of cardiovascular events in women 
with elevated high-sensitivity C-reactive protein or dyslipidemia: 
results from the Justification for the Use of Statins in Prevention: 
an   Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta- 
analysis of women from primary prevention trials. Circulation. 2010;121: 
1069–1077.
  327.  Duvernoy CS, Blumenthal R. The numbers are in: statins for the 
primary prevention of cardiovascular disease in women. Circulation. 
2010;121:1063–1065.
  328.  Highlights of prescribing information: Crestor (rosuvastatin cal-
cium) tablets. http://www.accessdata.fda.gov/drugsatfda_docs/
label/2010/021366s016lbl.pdf. Accessed 2010 Apr 16.
  329.  Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to 
make of JUPITER? Arch Int Med. 2010;170:1073–1077.
  330.  Jupiter criticism addressed again in more detail. 2010 Oct 1. http://www.
theheart.org/article/1130113.do. Accessed 2010 Oct 15.
  331.  Bassler D, Briel M, Montori VM, et al; STOPIT-2 Study Group. Stop-
ping randomized trials early for benefit and estimation of treatment 
effects: systematic review and meta-regression analysis. JAMA. 2010; 
303:1180–1187.
  332.  Montori VM, Devereaux PJ, Adhikari NKJ, et al. Random-
ized trials stopped early for benefit: a systematic review. JAMA. 
2005;294:2203–2209.
  333.  Pocock SJ. Current controversies in data monitoring for clinical trials. 
Clin Trials. 2006;3:513–521.
  334.  McCatney M. Leaping to conclusions. BMJ. 2008;336:1213–1214.
  335.  Department of Health and Human Services, United States Food and 
Drug Administration, Center for Drug Evaluation and Research. 
Transcript for the 2009 Dec 15, Meeting of the Endocrinologic 
and Metabolic Drugs Advisory Committee. http://www.fda.gov/ 
downloads/AdvisoryCommittees/CommitteesMeetingMaterials/
Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/
UCM200611.pdf. Accessed 2010 Oct 7.
  336.  De Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, 
cardiovascular diseases, and the rosuvastatin-JUPITER controversy: 
a critical reappraisal. Arch Intern Med. 2010;170:1032–1036.
  337.  De Lorgeril M. Answers to R. Ridker by M. de Lorgeril. 2010 
Jun 30. http://michel.delorgeril.info/dwnl/JUPITER/2010_Answers-to- 
Ridker-by-de-Lorgeril.pdf. Accessed 2010 Aug 15.
  338.  Glynn RJ, Danielson E, Fonseca FAH, et al. A randomized trial of 
rosuvastatin in the prevention of venous thromboembolism. N Engl J 
Med. 2009;360:1851–1861.
  339.  Ridker PM, Macfadyen J, Cressman M, Glynn RJ. Efficacy of rosuvas-
tatin among men and women with moderate chronic kidney disease and 
elevated high-sensitivity C-reactive protein: a secondary analysis from 
the JUPITER (Justification for the Use of Statins in Prevention – an 
Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 
2010;55:1266–1273.
  340.  Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. 
Rosuvastatin for primary prevention in older persons with elevated 
C-reactive protein and low to average low-density lipoprotein cho-
lesterol levels: exploratory analysis of a randomized trial. Ann Intern 
Med. 2010;152:488–496, W174.
  341.  Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation 
and cardiovascular disease: application to clinical and public health 
practice: a statement for healthcare professionals from the Centers for 
Disease Control and Prevention and the American Heart Association. 
Circulation. 2003;107:499–511.
  342.  Ridker PM, MacFadyen JG, Børge G, Nordestgaard BG, et al. Rosu-
vastatin for primary prevention among individuals with elevated 
high-sensitivity C-reactive protein and 5% to 10% and 10% to 20% 
10-year risk: implications of the Justification for Use of Statins in 
Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) 
Trial for “Intermediate Risk”. Circ Cardiovasc Qual Outcomes. 2010;3: 
447–452.
  343.  Kones R. Recent advances in the management of chronic stable 
angina I: approach to the patient, diagnosis, pathophysiology, risk 
stratification, and gender disparities. Vasc Health Risk Manag. 2010;6: 
635–656.
  344. Ridker PM, Glynn RJ. The JUPITER Trial: Responding to the critics. 
Am J Cardiol. 2010;106:1351–1356.
  345.  Harrington R, Ridker PM. The Bob Harrington Show. Episode #26: 
Dissecting the controversy around JUPITER with Dr Paul Ridker. 
http://radio.theheart.org/bob-harrington-show/2010/8/20/episode-26-
dissecting-the-controversy-around-jupiter-with-dr-paul-ridker. 2010   
Aug 27.
  346.  http://www.fda.gov/downloads/AdvisoryCommittees/Commit 
teesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugs 
AdvisoryCommittee/UCM193831.pdf. (FDA memorandum, 2009 
Nov 12, Appendix, page 11). Accessed 2010 Oct 7.
  347.  Friedlin B, Korn E. Stopping clinical trials early for benefit: impact 
on estimation. Clin Trials. 2009;6:119–125.
  348.  Korn EL, Friedlin B, Mooney M. Stopping or reporting early for 
positive results in randomized clinical trials: the National Cancer 
Institute Cooperative Experience from 1990 to 2005. J Clin Oncol. 
2009;27:1712–1721.
  349.  Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscu-
lar symptoms with high-dosage statin therapy in hyperlipidemic 
patients: the PRIMO study. Cardiovasc Drugs Ther. 2005;19: 
403–414.
  350.  Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety 
and efficacy of HMG-CoA reductase inhibitor monotherapy in the 
treatment of primary hypercholesterolemia. Ann Pharmacother. 
1995;29:743–759.
  351.  Garcia-Rodriguez LA, Masso-Gonzalez EL, Wallander MA, Johansson S. 
The safety of rosuvastatin in comparison with other statins in over 
100,000 statin users in UK primary care. Pharmacoepidemiol Drug 
Saf. 2008;17:943–952.
  352.  Garcia-Rodriguez LA, Gonzalez-Perez A, Stang MR, et al. The safety 
of rosuvastatin in comparison with other statins in over 25,000 statin 
users in the Saskatchewan Health Databases. Pharmacoepidemiol 
Drug Saf. 2008;17:953–961.
  353.  Sukhija R, Prayaga S, Marashdeh M, et al. Effect of statins on fasting 
plasma glucose in diabetic and nondiabetic patients. J Investig Med. 
2009;57:495–499.
  354. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvas-
tatin causes insulin resistance and increases ambient glycemia 
in hypercholesterolemic patients. J Am Coll Cardiol. 2010;55: 
1209–1216.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
412
Kones
  355.  Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV , Elisaf MS. 
Rosuvastatin treatment is associated with an increase in insulin resis-
tance in hyperlipidaemic patients with impaired fasting glucose. Int 
J Clin Pract. 2009;63;1308–1313.
  356.  Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy 
of cholesterol-lowering therapy in 18,696 people with diabetes in 
14 randomised trials of statins: a meta-analysis. Lancet. 2008;371: 
117–125.
  357.  Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident 
diabetes: a collaborative meta-analysis of randomised statin trials. 
Lancet. 2010;375:735–742.
  358.  Baker WL, Talati R, White CM, Coleman CI. Differing effect of 
statins on insulin sensitivity in non-diabetics: a systematic review and 
meta-analysis. Diab Res Clin Pract. 2010;87:98–107.
  359.  Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and 
functional consequences. Annu Rev Biochem. 1996;65;241–269.
  360.  Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol 
Rev. 2001;81:153–208.
  361.  Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune 
disease: from protein prenylation to immunomodulation. Nature Rev 
Immunol. 2006;6:358–370.
  362.  Chakrabarti R, Engleman EG. Interrelationships between mevalonate 
metabolism and the mitogenic signaling pathway in T lymphocyte 
proliferation. J Biol Chem. 1991;266:12216–12222.
  363.  Graham I, Atar D, Borch-Johnsen K, et al; Fourth Joint Task Force 
of the European Society of Cardiology and Other Societies on Car-
diovascular Disease Prevention in Clinical Practice (Constituted by 
representatives of nine societies and by invited experts). European 
guidelines on cardiovascular disease prevention in clinical practice: 
executive summary. Eur Heart J. 2007;28:2375–2414.
  364.  Liu PY, Chen JH, Lin LJ, Liao JK. Increased Rho kinase activity in a 
Taiwanese population with metabolic syndrome. J Am Coll Cardiol. 
2007;49:1619–1624.
  365.  Liao JK. Does it matter whether or not a lipid-lowering agent inhibits 
Rho kinase? Curr Atheroscler Rep. 2007;9:384–388.
  366.  Dong M, Yan BP, Liao JK, Lam YY, Yip GWK, Yu C-M. Rho-kinase 
inhibition: a novel therapeutic target for the treatment of cardiovascular 
diseases. Drug Discov Today. 2010;15:622–629.
  367.  Brozinick JT Jr, Berkemeier BA, Elmendorf JS. “Acting” on GLUT4: 
membrane and cytoskeletal components of insulin action. Curr Dia-
betes Rev. 2007;3:111–122.
  368.  Horvath EM, Tackett L, Elmendorf JS. A novel membrane-based 
anti-diabetic action of atorvastatin. Biochem Biophys Res Commun. 
2008;372:639–643.
  369.  Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. 
Effects of statins on the adipocyte maturation and expression of 
glucose transporter 4 (SLC2A4): implications in glycemic control. 
Diabetologia. 2006;49:1881–1892.
  370.  White CM. A review of the pharmacologic and pharmacokinetic 
aspects of rosuvastatin. J Clin Pharmacol. 2002;42:963–970.
 371.  Mita T, Watada H, Nakayama S, et al. Preferable effect of pravastatin 
compared to atorvastatin on beta cell function in Japanese early-state   
type 2 diabetes with hypercholesterolemia. Endocr J. 2007;54: 
441–447.
  372.  Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, 
but not pravastatin, of glucose-induced cytosolic Ca2+ signaling and 
insulin secretion due to blockade of L-type Ca2+ channels in rat islet 
b-cells. Br J Pharmacol. 1999;126:1205–1213.
  373.  Siddals KW, Marshman E, Westwood M, Gibson JM. Abrogation of 
insulin-like growth factor-I (IGF-I) and insulin action by mevalonic 
acid depletion: synergy between protein prenylation and receptor 
glycosylation pathways. J Biol Chem. 2004;279:38353–38359.
  374.  Otokozawa S, Ai M, van Himbergen T, et al. Effects of intensive 
atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and 
remnant lipoprotein cholesterol levels. Atherosclerosis. 2009;205: 
197–201.
  375.  American Diabetes Association. Standards of Medical Care in 
  Diabetes – 2009. Diabetes Care. 2009;32(Suppl 1):S13–S61.
  376.  Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, 
Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety 
of statins. Stroke. 2002;33:2337–2341.
  377.  Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. 
JAMA. 2003;289:1681–1690.
  378.  Tomlinson SS, Mangione KK. Potential adverse effects of statins on 
muscle. Phys Ther. 2005;85:459–465.
  379.  SEARCH Collaborative Group, Link E, Parish S, Armitage J, et al. 
SLCO1B1 variants and statin-induced myopathy – a genomewide 
study. N Eng J Med. 2008;359:789–799.
  380.  Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, 
a muscle-specific F-box protein highly expressed during muscle   
atrophy. Proc Natl Acad Sci U S A. 2001;98:14440–14445.
  381.  Hanai J, Cao P, Tanksale P, et al. The muscle-specific ubiquitin ligase 
atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin 
Invest. 2007;117:3940–3951.
  382.  Cao P, Hanai J-i, Tanksale P, Imamura S, Sukhatme VP, Lecker 
SH. Statin-induced muscle damage and atrogin-1 induction is 
the result of a geranylgeranylation defect. FASEB J. 2009;23: 
2844–2854.
  383.  Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, et al. Human 
skeletal muscle drug transporters determine local exposure and toxicity 
of statins. Circ Res. 2010;106:297–306.
  384.  Dorajoo R, Pereira BP, Yu Z, et al. Role of multidrug resistance-
associated protein-1 transporter in statin-induced myopathy. Life Sci. 
2008;82:823–830.
  385.  Masters BA, Palmoski MJ, Glint OP, Gregg RE, Wang-Iverson D, 
Durham SK. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl 
coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvas-
tatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol. 
1995;131:163–174.
  386.  Thalacker-Mercer A, Baker M, Calderon C, Bamman M. Simvastatin 
Reduces Human Primary Satellite Cell Proliferation in Culture. Pre-
sentation, American Physiological Society, The Integrative Biology 
of Exercise V . 2008 Sep 24–27, Hilton Head, SC. http://www.the-aps.
org/press/journal/08/32.htm and http://www.the-aps.org/Video/Clips/
AnnaThalacker-Mercer.htm. Accessed 2010 Nov 20.
  387.  Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-
associated myopathy: a systematic review. J Am Coll Cardiol. 
2007;49:2231–2237.
  388.  Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. 
Am J Physiol Cell Physiol. 2006;291:C1208–C1212.
  389.  Sirvent P, Mercier J, Lacampagne A. New insights into mecha-
nisms of statin-associated myotoxicity. Curr Opin Pharmacol. 
2008;8:333–338.
  390.  Needham M, Fabian V , Knezevic W, et al. Progressive myopathy with 
upregulation of MHC-I associated with statin therapy. Neuromuscul 
Disord. 2007;17:194–200.
  391.  Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-
mediated necrotizing myopathy associated with statins. Muscle Nerve. 
2010;41:185–190.
  392.  Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD. 
Molecular basis of statin-associated myopathy. Atherosclerosis. 2009; 
202:18–28.
  393.  Mas E, Mori TA. Coenzyme Q10 and statin myalgia: what is the 
evidence? Curr Atheroscler Rep. 2010;12;407–413.
  394.  Vandenberg BF, Robinson J. Management of the patient with statin 
intolerance. Curr Atheroscler Rep. 2010;12:48–57.
  395.  Mammen AL, Amato AA. Statin myopathy: a review of recent prog-
ress. Curr Opin Rheumatol. 2010;22:644–650.
  396.  Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin 
safety by muscle experts. Am J Cardiol. 2006;97:69C–76C.
  397.  Armitage J. The safety of statins in clinical practice. Lancet. 
2007;370:1781–1790.Drug Design, Development and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal
Drug Design, Development and Therapy is an international, peer-
reviewed open-access journal that spans the spectrum of drug design 
and development through to clinical applications. Clinical outcomes, 
patient safety, and programs for the development and effective, safe, 
and sustained use of medicines are a feature of the journal, which 
has also been accepted for indexing on PubMed Central. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
413
Rosuvastatin, inflammation, CRP, and JUPITER
  398.  Ford ES, Li C, Zhao G, Tsai J. Trends in obesity and abdominal obesity 
among adults in the United States from 1999–2008. Int J Obes (Lond). 
2010 Sep 7. [Epub ahead of print].
  399.  Filion KB, Genest J, Joseph L, et al. The metabolic syndrome and 
cardiovascular risk: a systematic review and meta-analysis. J Am Coll 
Cardiol. 2010;56:1113–1132.
  400.  DeMazumder D, Hasan RK, Blumenthal RS, Michos ED, Jones 
S. Should statin therapy be allocated on the basis of global risk 
or on the basis of randomized trial evidence? Am J Cardiol. 
2010;106:905–909.
  401.  Nambi V , Ballantyne CM. “Risky Business”: ten years is not a lifetime. 
Circulation. 2009;119:362–364.
  402. Lloyd-Jones DM, Hong Y, Labarthe D, et al; American Heart 
Association Strategic Planning Task Force and Statistics Commit-
tee. Defining and setting national goals for cardiovascular health 
promotion and disease reduction: the American Heart Association’s 
strategic Impact Goal through 2020 and beyond. Circulation. 2010; 
121:586–613.
  403.  Webster R, Heeley E. Perceptions of risk: understanding cardiovascular 
disease. Risk Management and Healthcare Policy. 2010:3:49–60.